메뉴 건너뛰기




Volumn 56, Issue 5-6, 1999, Pages 481-506

Chemotherapy and immunotherapy of malignant glioma: Molecular mechanisms and clinical perspectives

Author keywords

Apo2L (TRAIL); Apoptosis; CD95 (Fas Apo1); Chemotherapy; Immunotherapy; Malignant glioma

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; AZIRIDINYLBENZOQUINONE; CANCER VACCINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; CYTOTOXIC AGENT; DACARBAZINE; DEXAMETHASONE; ETOPOSIDE; FAS ANTIGEN; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; IFOSFAMIDE; IMMUNOMODULATING AGENT; LIGAND; LOMUSTINE; MERCAPTOPURINE; NITROSOUREA; PROCARBAZINE; STEROID; TEMOZOLOMIDE; UNINDEXED DRUG; VINCA ALKALOID; VINCRISTINE;

EID: 0032729849     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180050447     Document Type: Review
Times cited : (55)

References (264)
  • 1
    • 0026076377 scopus 로고
    • The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas
    • 1 Quigley M. R. and Maroon J. C. (1991) The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 29: 385-388
    • (1991) Neurosurgery , vol.29 , pp. 385-388
    • Quigley, M.R.1    Maroon, J.C.2
  • 2
    • 0030859359 scopus 로고    scopus 로고
    • Chemotherapy of human malignant glioma: Prevention of efficacy by dexamethasone?
    • 2 Weller M., Schmidt C., Roth W. and Dichgans J. (1997) Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology 48: 1704-1709
    • (1997) Neurology , vol.48 , pp. 1704-1709
    • Weller, M.1    Schmidt, C.2    Roth, W.3    Dichgans, J.4
  • 3
    • 0032563826 scopus 로고    scopus 로고
    • Dexamethasone-mediated protection from drug cytotoxicity: Association with p21WAF1/CIP1 protein accumulation?
    • 3 Naumann U., Durka S. and Weller M. (1998) Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation? Oncogene 17: 1567-1575
    • (1998) Oncogene , vol.17 , pp. 1567-1575
    • Naumann, U.1    Durka, S.2    Weller, M.3
  • 4
    • 0029841263 scopus 로고    scopus 로고
    • Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas
    • 4 Kim L., Hochberg F. H., Thornton A. F., Harsh G. R. 4th, Patel H., Finkelstein D. et al. (1996) Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J. Neurosurg. 85: 602-607
    • (1996) J. Neurosurg. , vol.85 , pp. 602-607
    • Kim, L.1    Hochberg, F.H.2    Thornton, A.F.3    Harsh G.R. IV4    Patel, H.5    Finkelstein, D.6
  • 6
    • 0026576153 scopus 로고
    • Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas
    • 6 Jeremic B., Jovanovic D., Djuric L. J., Jevremovic S. and Mijatovic L. J. (1992) Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas. J. Chemother. 4: 123-126
    • (1992) J. Chemother. , vol.4 , pp. 123-126
    • Jeremic, B.1    Jovanovic, D.2    Djuric, L.J.3    Jevremovic, S.4    Mijatovic, L.J.5
  • 7
    • 0025239917 scopus 로고
    • Superiority of post-radiotherapyadjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report
    • 7 Levin V. A., Silver P., Hannigan J., Wara W. M., Gutin P. H., Davis R. L. et al. (1990) Superiority of post-radiotherapyadjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys. 18: 321-324
    • (1990) Int. J. Radiat. Oncol. Biol. Phys. , vol.18 , pp. 321-324
    • Levin, V.A.1    Silver, P.2    Hannigan, J.3    Wara, W.M.4    Gutin, P.H.5    Davis, R.L.6
  • 8
    • 0028911680 scopus 로고
    • Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas
    • 8 Levin V. A., Prados M. R., Wara W. M., Davis R. L., Gutin P. H., Phillips T. L, et al. (1995) Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. Int. J. Radial. Oncol. Biol. Phys. 32: 75-83
    • (1995) Int. J. Radial. Oncol. Biol. Phys. , vol.32 , pp. 75-83
    • Levin, V.A.1    Prados, M.R.2    Wara, W.M.3    Davis, R.L.4    Gutin, P.H.5    Phillips, T.L.6
  • 9
    • 0027516695 scopus 로고
    • Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
    • 9 Fine H. A., Dear K. B., Loeffler J. S., Black P. M. and Canellos G. P. (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2597
    • (1993) Cancer , vol.71 , pp. 2585-2597
    • Fine, H.A.1    Dear, K.B.2    Loeffler, J.S.3    Black, P.M.A.4    Canellos, G.P.5
  • 10
    • 0024955830 scopus 로고
    • The role of chemotherapy in the treatment of gliomas in adults
    • 10 Stewart D. J. (1989) The role of chemotherapy in the treatment of gliomas in adults. Cancer Treat. Rev. 16: 129-160
    • (1989) Cancer Treat. Rev. , vol.16 , pp. 129-160
    • Stewart, D.J.1
  • 11
    • 0018125603 scopus 로고
    • Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial
    • 11 Walker M. D., Alexander E. Jr, Hunt W. E., MacCarty C. S., Mahaley M. S. Jr, Mealey J. Jr et al. (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg. 49: 333-343
    • (1978) J. Neurosurg. , vol.49 , pp. 333-343
    • Walker, M.D.1    Alexander E., Jr.2    Hunt, W.E.3    MacCarty, C.S.4    Mahaley M.S., Jr.5    Mealey J., Jr.6
  • 12
    • 0027145640 scopus 로고
    • Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: A phase II study
    • 12 Ameri A., Poisson M., Chen Q. M. and Delattre J. Y. (1993) Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study. J. Neurooncol. 17: 43-46
    • (1993) J. Neurooncol. , vol.17 , pp. 43-46
    • Ameri, A.1    Poisson, M.2    Chen, Q.M.3    Delattre, J.Y.4
  • 13
    • 0031047440 scopus 로고    scopus 로고
    • Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: A phase II study
    • 13 Ameri A., Poisson M., Chauveinc L., Chen Q. M. and Delattre J. Y. (1997) Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: a phase II study. J. Neurooncol. 32: 155-160
    • (1997) J. Neurooncol. , vol.32 , pp. 155-160
    • Ameri, A.1    Poisson, M.2    Chauveinc, L.3    Chen, Q.M.4    Delattre, J.Y.5
  • 14
    • 0030933487 scopus 로고    scopus 로고
    • Thiotepa and etoposide treatment of recurrent malignant gliomas: Phase I study
    • 14 Balmaceda C., Fetell M. R. and Hesdorffer C. (1997) Thiotepa and etoposide treatment of recurrent malignant gliomas: phase I study. Cancer Chemother. Pharmacol. 40: 72-74
    • (1997) Cancer Chemother. Pharmacol. , vol.40 , pp. 72-74
    • Balmaceda, C.1    Fetell, M.R.2    Hesdorffer, C.3
  • 15
    • 0027071631 scopus 로고
    • Carboplatin combined with carmustine and etoposide in the treatment of glioblastoma
    • 15 Boiardi A., Silvani A., Milanesi I., Botturi M. and Broggi G. (1992) Carboplatin combined with carmustine and etoposide in the treatment of glioblastoma. Ital. J. Neurol. Sci. 13: 717-722
    • (1992) Ital. J. Neurol. Sci. , vol.13 , pp. 717-722
    • Boiardi, A.1    Silvani, A.2    Milanesi, I.3    Botturi, M.4    Broggi, G.5
  • 16
    • 0026536938 scopus 로고
    • Efficacy of '8-drugs-in-one-day' combination in treatment of recurrent GBM patients
    • 16 Boiardi A., Silvani A., Milanesi I., Broggi G. and Fariselli L. (1992) Efficacy of '8-drugs-in-one-day' combination in treatment of recurrent GBM patients. J. Neurooncol. 12: 153-158
    • (1992) J. Neurooncol. , vol.12 , pp. 153-158
    • Boiardi, A.1    Silvani, A.2    Milanesi, I.3    Broggi, G.4    Fariselli, L.5
  • 17
    • 0031964962 scopus 로고    scopus 로고
    • Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: A phase II study
    • 17 Brandes A. A., Rigon A., Zampieri P., Ermani M., Carollo C., Altavilla G. et al. (1998) Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. Cancer 82: 355-361
    • (1998) Cancer , vol.82 , pp. 355-361
    • Brandes, A.A.1    Rigon, A.2    Zampieri, P.3    Ermani, M.4    Carollo, C.5    Altavilla, G.6
  • 18
    • 0028939248 scopus 로고
    • Concurrent cisplatin therapy and iodine 125 brachytherapy for recurrent malignant brain tumors
    • 18 Chamberlain M. C., Barba D., Kormanik P., Berson A. M., Saunders W. M. and Shea M. C. (1995) Concurrent cisplatin therapy and iodine 125 brachytherapy for recurrent malignant brain tumors. Arch. Neurol. 52: 162-167
    • (1995) Arch. Neurol. , vol.52 , pp. 162-167
    • Chamberlain, M.C.1    Barba, D.2    Kormanik, P.3    Berson, A.M.4    Saunders, W.M.5    Shea, M.C.6
  • 19
    • 0029166912 scopus 로고
    • Salvage chemotherapy with paclitaxel for recurrent primary brain tumors
    • 19 Chamberlain M. C. and Kormanik P. (1995) Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J. Clin. Oncol. 13: 2066-2071
    • (1995) J. Clin. Oncol. , vol.13 , pp. 2066-2071
    • Chamberlain, M.C.1    Kormanik, P.2
  • 21
    • 0027175888 scopus 로고
    • Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma
    • 21 Dinapoli R. P., Brown L. D., Arusell R. M., Earle J. D., O'Fallon J. R., Buckner J. C. et al. (1993) Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J. Clin. Oncol. 11: 1316-1321
    • (1993) J. Clin. Oncol. , vol.11 , pp. 1316-1321
    • Dinapoli, R.P.1    Brown, L.D.2    Arusell, R.M.3    Earle, J.D.4    O'Fallon, J.R.5    Buckner, J.C.6
  • 22
    • 0027288999 scopus 로고
    • A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: A southwest oncology group study
    • 22 Eyre H. J., Crowley J. J., Townsend J. J., Eltringham J. R., Morantz R. A., Schulman S. F. et al. (1993) A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J. Neurosurg. 78: 909-914
    • (1993) J. Neurosurg. , vol.78 , pp. 909-914
    • Eyre, H.J.1    Crowley, J.J.2    Townsend, J.J.3    Eltringham, J.R.4    Morantz, R.A.5    Schulman, S.F.6
  • 23
    • 0030762796 scopus 로고    scopus 로고
    • Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions
    • 23 Fetell M. R., Grossman S. A., Fisher J. D., Erlanger B., Rowinsky E., Stockel J. et al. (1997) Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. J. Clin. Oncol. 15: 3121-3128
    • (1997) J. Clin. Oncol. , vol.15 , pp. 3121-3128
    • Fetell, M.R.1    Grossman, S.A.2    Fisher, J.D.3    Erlanger, B.4    Rowinsky, E.5    Stockel, J.6
  • 24
    • 0029800151 scopus 로고    scopus 로고
    • Phase II trial of docetaxel in patients with recurrent malignant glioma: A study of the National Cancer Institute of Canada Clinical Trials Group
    • 24 Forsyth P., Cairncross G., Stewart D., Goodyear M., Wainman N. and Eisenhauer E. (1996) Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group. Invest. New Drugs 14: 203-206
    • (1996) Invest. New Drugs , vol.14 , pp. 203-206
    • Forsyth, P.1    Cairncross, G.2    Stewart, D.3    Goodyear, M.4    Wainman, N.5    Eisenhauer, E.6
  • 25
    • 0030053959 scopus 로고    scopus 로고
    • Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma
    • 25 Fulton D., Urtasun R. and Forsyth P. (1996) Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J. Neurooncol. 27: 149-155
    • (1996) J. Neurooncol. , vol.27 , pp. 149-155
    • Fulton, D.1    Urtasun, R.2    Forsyth, P.3
  • 26
    • 0031692882 scopus 로고    scopus 로고
    • Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North central cancer treatment group results
    • 26 Galanis E., Buckner J. C., Burch P. A., Schaefer P. L., Dinapoli R. P., Novotny P. J. et al. (1998) Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. J. Clin. Oncol. 16: 2953-2958
    • (1998) J. Clin. Oncol. , vol.16 , pp. 2953-2958
    • Galanis, E.1    Buckner, J.C.2    Burch, P.A.3    Schaefer, P.L.4    Dinapoli, R.P.5    Novotny, P.J.6
  • 27
    • 0030793974 scopus 로고    scopus 로고
    • Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma
    • 27 Grossman S. A., Wharam M., Sheidler V., Kleinberg L., Zeltzman M., Yue N. et al. (1997) Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J. Clin. Oncol. 15: 2596-2603
    • (1997) J. Clin. Oncol. , vol.15 , pp. 2596-2603
    • Grossman, S.A.1    Wharam, M.2    Sheidler, V.3    Kleinberg, L.4    Zeltzman, M.5    Yue, N.6
  • 28
    • 0031818560 scopus 로고    scopus 로고
    • Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme
    • 28 Gruber M. L., Glass J., Choudhri H. and Nirenberg A. (1998) Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme. Am. J. Clin. Oncol. 21: 338-340
    • (1998) Am. J. Clin. Oncol. , vol.21 , pp. 338-340
    • Gruber, M.L.1    Glass, J.2    Choudhri, H.3    Nirenberg, A.4
  • 29
    • 0027182175 scopus 로고
    • An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors
    • 29 Halperin E. C., Gaspar L., Imperato J., Salter M., Herndon J. 2nd and Dowling S. (1993) An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. Am. J. Clin. Oncol. 16: 277-283
    • (1993) Am. J. Clin. Oncol. , vol.16 , pp. 277-283
    • Halperin, E.C.1    Gaspar, L.2    Imperato, J.3    Salter, M.4    Herndon J. II5    Dowling, S.6
  • 30
    • 9044237687 scopus 로고    scopus 로고
    • A phase III randomized prospective trial of external beam radiotherapy. Mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain
    • 30 Halperin E. C., Herndon J., Schold S. C., Brown M., Vick N., Cairncross J. G. et al. (1996) A phase III randomized prospective trial of external beam radiotherapy. mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. Int. J. Radiat. Oncol. Biol. Phys. 34: 793-802
    • (1996) Int. J. Radiat. Oncol. Biol. Phys. , vol.34 , pp. 793-802
    • Halperin, E.C.1    Herndon, J.2    Schold, S.C.3    Brown, M.4    Vick, N.5    Cairncross, J.G.6
  • 31
    • 0031882420 scopus 로고    scopus 로고
    • A therapeutic trial of radiation therapy with vincristine, etoposide, and procarbazine (VVP) in high grade intracranial gliomas an eastern cooperative oncology group study (E2392)
    • 31 Hellman R., Neuberg D. S., Wagner H., Grunnet M., Robins H. I., Karp D. et al. (1998) A therapeutic trial of radiation therapy with vincristine, etoposide, and procarbazine (VVP) in high grade intracranial gliomas an Eastern Cooperative Oncology Group Study (E2392). J. Neurooncol. 37: 55-62
    • (1998) J. Neurooncol. , vol.37 , pp. 55-62
    • Hellman, R.1    Neuberg, D.S.2    Wagner, H.3    Grunnet, M.4    Robins, H.I.5    Karp, D.6
  • 32
    • 0031882610 scopus 로고    scopus 로고
    • Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine a phase-II study
    • 32 Hildebrand J., De Witte O. and Sahmoud T. (1998) Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine a phase-II study. J. Neurooncol. 37: 155-160
    • (1998) J. Neurooncol. , vol.37 , pp. 155-160
    • Hildebrand, J.1    De Witte, O.2    Sahmoud, T.3
  • 33
    • 0029843617 scopus 로고    scopus 로고
    • Phase II study of DTIC, ACNU, and vincristine combination chemotherapy for supratentorial malignant astrocytomas
    • 33 Ikeda J., Aida T., Sawamura Y., Abe H., Kaneko S., Kashiwaba T. et al. (1996) Phase II study of DTIC, ACNU, and vincristine combination chemotherapy for supratentorial malignant astrocytomas. Neurol. Med. Chir. Tokyo 36: 555-558
    • (1996) Neurol. Med. Chir. Tokyo , vol.36 , pp. 555-558
    • Ikeda, J.1    Aida, T.2    Sawamura, Y.3    Abe, H.4    Kaneko, S.5    Kashiwaba, T.6
  • 34
  • 35
    • 0028138511 scopus 로고
    • Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: A phase Ii study
    • 35 Jeremie B., Grujicie D., Antunovic V., Djuric L., Stojanovic M. and Shibamoto Y. (1994) Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study. Int. J. Radiat. Oncol. Biol. Phys. 30: 1179-1185
    • (1994) Int. J. Radiat. Oncol. Biol. Phys. , vol.30 , pp. 1179-1185
    • Jeremie, B.1    Grujicie, D.2    Antunovic, V.3    Djuric, L.4    Stojanovic, M.5    Shibamoto, Y.6
  • 36
    • 0028867792 scopus 로고
    • Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas
    • 36 Kiu M. C., Chang C. N., Cheng W. C., Lin T. K., Wong C. W., Tang S. G. et al. (1995) Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas. J. Neurooncol. 25: 215-220
    • (1995) J. Neurooncol. , vol.25 , pp. 215-220
    • Kiu, M.C.1    Chang, C.N.2    Cheng, W.C.3    Lin, T.K.4    Wong, C.W.5    Tang, S.G.6
  • 37
    • 0029851979 scopus 로고    scopus 로고
    • Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas
    • 37 Kyritsis A. P., Yung W. K., Jaeckle K. A., Bruner J., Gleason M. J., Ictech S. E. et al. (1996) Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. Neurosurgery 39: 921-926
    • (1996) Neurosurgery , vol.39 , pp. 921-926
    • Kyritsis, A.P.1    Yung, W.K.2    Jaeckle, K.A.3    Bruner, J.4    Gleason, M.J.5    Ictech, S.E.6
  • 38
    • 0032005352 scopus 로고    scopus 로고
    • Fractionated stereotactic radiosurgery and concurrent taxol in recurrent glioblastoma multiforme: A preliminary report
    • 38 Lederman G., Arbit E., Odaimi M., Lombardi E., Wrzolek M. and Wronski M. (1998) Fractionated stereotactic radiosurgery and concurrent taxol in recurrent glioblastoma multiforme: a preliminary report. Int. J. Radial. Oncol. Biol. Phys. 40: 661-666
    • (1998) Int. J. Radial. Oncol. Biol. Phys. , vol.40 , pp. 661-666
    • Lederman, G.1    Arbit, E.2    Odaimi, M.3    Lombardi, E.4    Wrzolek, M.5    Wronski, M.6
  • 39
    • 0026695162 scopus 로고
    • Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance
    • 39 Levin V. A. and Prados M. D. (1992) Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J. Clin. Oncol. 10: 766-771
    • (1992) J. Clin. Oncol. , vol.10 , pp. 766-771
    • Levin, V.A.1    Prados, M.D.2
  • 40
    • 0029161882 scopus 로고
    • Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme
    • 40 Levin V. A., Maor M. H., Thall P. F., Yung W. K., Bruner J., Sawaya R. et al. (1995) Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 33: 357-364
    • (1995) Int. J. Radiat. Oncol. Biol. Phys. , vol.33 , pp. 357-364
    • Levin, V.A.1    Maor, M.H.2    Thall, P.F.3    Yung, W.K.4    Bruner, J.5    Sawaya, R.6
  • 41
    • 0030067640 scopus 로고    scopus 로고
    • Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: A phase II study
    • 41 Lunardi P., Osman Farah J., Mastronardi L., Puzzilli F. and Lo Bianco F. M. (1996) Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study. Acta Neurochir. Wien 138: 215-220
    • (1996) Acta Neurochir. Wien , vol.138 , pp. 215-220
    • Lunardi, P.1    Osman Farah, J.2    Mastronardi, L.3    Puzzilli, F.4    Lo Bianco, F.M.5
  • 42
    • 0028618433 scopus 로고
    • Superiority of PCNU over AZQ in the treatment of primary brain tumors: Results of a prospective randomized trial (81-20) by the brain tumor study group
    • 42 Malkin M. G., Green S. B., Byar D. P., Strike T. A., Burger P. C., Vogel F. S. et al. (1994) Superiority of PCNU over AZQ in the treatment of primary brain tumors: results of a prospective randomized trial (81-20) by the Brain Tumor Study Group. J. Neurooncol. 22: 55-65
    • (1994) J. Neurooncol. , vol.22 , pp. 55-65
    • Malkin, M.G.1    Green, S.B.2    Byar, D.P.3    Strike, T.A.4    Burger, P.C.5    Vogel, F.S.6
  • 43
    • 0027160503 scopus 로고
    • Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas
    • 43 Newton H. B., Bromberg J., Junck L., Page M. A. and Greenberg H. S. (1993) Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. J. Neurooncol. 15: 257-263
    • (1993) J. Neurooncol. , vol.15 , pp. 257-263
    • Newton, H.B.1    Bromberg, J.2    Junck, L.3    Page, M.A.4    Greenberg, H.S.5
  • 45
    • 0031963150 scopus 로고    scopus 로고
    • Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors
    • 45 Prados M. D., Larson D. A., Lamborn K., McDermott M. W., Sneed P. K., Wara W. M. et al. (1998) Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. Int. J. Radiat. Oncol. Biol. Phys. 40: 57-63
    • (1998) Int. J. Radiat. Oncol. Biol. Phys. , vol.40 , pp. 57-63
    • Prados, M.D.1    Larson, D.A.2    Lamborn, K.3    McDermott, M.W.4    Sneed, P.K.5    Wara, W.M.6
  • 46
    • 0028129321 scopus 로고
    • Multimodality management of recurrent adult malignant gliomas: Results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery
    • 46 Rostomily R. C., Spence A. M., Duong D., McCormick K., Bland M. and Berger M. S. (1994) Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 35: 378-388
    • (1994) Neurosurgery , vol.35 , pp. 378-388
    • Rostomily, R.C.1    Spence, A.M.2    Duong, D.3    McCormick, K.4    Bland, M.5    Berger, M.S.6
  • 47
    • 0030445597 scopus 로고    scopus 로고
    • Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: A phase II study
    • 47 Sanson M., Ameri A., Monjour A., Sahmoud T., Ronchin P., Poisson M. et al. (1996) Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. Eur. J. Cancer 32A: 2229-2235
    • (1996) Eur. J. Cancer , vol.32 A , pp. 2229-2235
    • Sanson, M.1    Ameri, A.2    Monjour, A.3    Sahmoud, T.4    Ronchin, P.5    Poisson, M.6
  • 49
    • 0030791352 scopus 로고    scopus 로고
    • Clinical trial of external beam-radiotherapy combined with daily administration of low-dose cisplatin for supratentorial glioblastoma multiforme a pilot study
    • 49 Shinoda J., Sakai N., Hara A., Ueda T., Sakai H. and Nakatani K. (1997) Clinical trial of external beam-radiotherapy combined with daily administration of low-dose cisplatin for supratentorial glioblastoma multiforme a pilot study. J. Neurooncol. 35: 73-80
    • (1997) J. Neurooncol. , vol.35 , pp. 73-80
    • Shinoda, J.1    Sakai, N.2    Hara, A.3    Ueda, T.4    Sakai, H.5    Nakatani, K.6
  • 50
    • 0026544396 scopus 로고
    • Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure
    • 50 Spence A. M., Berger M. S., Livingston R. B., Ali Osman F. and Griffin B. (1992) Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. J. Neurooncol. 12: 187-191
    • (1992) J. Neurooncol. , vol.12 , pp. 187-191
    • Spence, A.M.1    Berger, M.S.2    Livingston, R.B.3    Ali Osman, F.4    Griffin, B.5
  • 51
    • 0029034516 scopus 로고
    • A phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults
    • 51 Stewart D. J., Dahrouge S. and Soltys K. (1995) A phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults. J. Neurooncol. 23: 249-252
    • (1995) J. Neurooncol. , vol.23 , pp. 249-252
    • Stewart, D.J.1    Dahrouge, S.2    Soltys, K.3
  • 52
    • 0031040639 scopus 로고    scopus 로고
    • Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas
    • 52 Stewart D. J., Dahrouge S., Agboola O. and Girard A. (1997) Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas. J. Neurooncol. 32: 161-168
    • (1997) J. Neurooncol. , vol.32 , pp. 161-168
    • Stewart, D.J.1    Dahrouge, S.2    Agboola, O.3    Girard, A.4
  • 53
    • 0026595777 scopus 로고
    • Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas
    • 53 Yung W. K., Janus T. J., Maor M. and Feun L. G. (1992) Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. J. Neurooncol. 12: 131-135
    • (1992) J. Neurooncol. , vol.12 , pp. 131-135
    • Yung, W.K.1    Janus, T.J.2    Maor, M.3    Feun, L.G.4
  • 55
    • 0032005473 scopus 로고    scopus 로고
    • Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: A retrospective comparison of survival data from the northern california oncology group (NCOG) and radiation therapy oncology group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma
    • 55 Prados M. D., Scott C. B., Rotman M., Rubin P., Murray K., Sause W. et al. (1998) Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma. Int. J. Radial. Oncol. Biol. Phys. 40: 653-659
    • (1998) Int. J. Radial. Oncol. Biol. Phys. , vol.40 , pp. 653-659
    • Prados, M.D.1    Scott, C.B.2    Rotman, M.3    Rubin, P.4    Murray, K.5    Sause, W.6
  • 57
    • 0028107037 scopus 로고
    • Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas
    • 57 Hildebrand J., Sahmoud T., Mignolet F., Brucher J. M. and Afra D. (1994) Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology 44: 1479-1483
    • (1994) Neurology , vol.44 , pp. 1479-1483
    • Hildebrand, J.1    Sahmoud, T.2    Mignolet, F.3    Brucher, J.M.4    Afra, D.5
  • 58
    • 0023221237 scopus 로고
    • Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors
    • 58 Levin V. A., Chamberlain M. C., Prados M. D., Choucair A. K., Berger M. S., Silver P. et al. (1987) Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors. Cancer Treat. Rep. 71: 459-464
    • (1987) Cancer Treat. Rep. , vol.71 , pp. 459-464
    • Levin, V.A.1    Chamberlain, M.C.2    Prados, M.D.3    Choucair, A.K.4    Berger, M.S.5    Silver, P.6
  • 59
    • 0028278131 scopus 로고
    • Clinical and biological studies of estramustine phosphate as a novel radiation sensitizer
    • 59 Kim J. H., Khil M. S., Kim S. H., Ryu S. and Gabel M. (1994) Clinical and biological studies of estramustine phosphate as a novel radiation sensitizer. Int. J. Radiat. Oncol. Biol. Phys. 29: 555-557
    • (1994) Int. J. Radiat. Oncol. Biol. Phys. , vol.29 , pp. 555-557
    • Kim, J.H.1    Khil, M.S.2    Kim, S.H.3    Ryu, S.4    Gabel, M.5
  • 60
    • 0025878868 scopus 로고
    • Phase II study of fotemustine in recurrent supratentorial malignant gliomas
    • 60 Frenay M., Giroux B., Khoury S., Derlon J. M. and Namer M. (1991) Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur. J. Cancer 27: 852-856
    • (1991) Eur. J. Cancer , vol.27 , pp. 852-856
    • Frenay, M.1    Giroux, B.2    Khoury, S.3    Derlon, J.M.4    Namer, M.5
  • 61
    • 0032910182 scopus 로고    scopus 로고
    • Gemcitabine cytotoxicity of human malignant glioma cells: Modulation by antioxidants, BCL-2 and dexamethasone
    • 61 Rieger J., Durka S., Streffer J., Dichgans J. and Weller M. (1999) Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. Eur. J. Pharmacol. 365: 301-308
    • (1999) Eur. J. Pharmacol. , vol.365 , pp. 301-308
    • Rieger, J.1    Durka, S.2    Streffer, J.3    Dichgans, J.4    Weller, M.5
  • 62
    • 0026576715 scopus 로고
    • Anthracyclines and their C-13 alcohol metabolites: Growth inhibition and DNA damage following incubation with human tumor cells in culture
    • 62 Kuffel M. J., Reid J. M. and Ames M. M. (1992) Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother. Pharmacol. 30: 51-57
    • (1992) Cancer Chemother. Pharmacol. , vol.30 , pp. 51-57
    • Kuffel, M.J.1    Reid, J.M.2    Ames, M.M.3
  • 63
    • 0026766720 scopus 로고
    • Phase II study of weekly intravenous menogaril in the treatment of recurrent astrocytomas in adults
    • 63 Stewart D. J., Hugenholtz H., DaSilva V. F., Benoit B. G., Richard M. T., Verma S. et al. (1992) Phase II study of weekly intravenous menogaril in the treatment of recurrent astrocytomas in adults. J. Neurooncol. 13: 183-188
    • (1992) J. Neurooncol. , vol.13 , pp. 183-188
    • Stewart, D.J.1    Hugenholtz, H.2    DaSilva, V.F.3    Benoit, B.G.4    Richard, M.T.5    Verma, S.6
  • 65
    • 0029063579 scopus 로고
    • Phase 1 study of phenylacetate administered twice daily to patients with cancer
    • 65 Thibault A., Samid D., Cooper M. R., Figg W. D., Tompkins A. C., Patronas N. et al. (1995) Phase 1 study of phenylacetate administered twice daily to patients with cancer. Cancer 75: 2932-2938
    • (1995) Cancer , vol.75 , pp. 2932-2938
    • Thibault, A.1    Samid, D.2    Cooper, M.R.3    Figg, W.D.4    Tompkins, A.C.5    Patronas, N.6
  • 66
    • 9344238245 scopus 로고    scopus 로고
    • Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: An open pilot study
    • 66 Salazar A. M., Levy H. B., Ondra S., Kende M., Scherokman B., Brown D, et al. (1996) Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 38: 1096-1103
    • (1996) Neurosurgery , vol.38 , pp. 1096-1103
    • Salazar, A.M.1    Levy, H.B.2    Ondra, S.3    Kende, M.4    Scherokman, B.5    Brown, D.6
  • 67
    • 0030994384 scopus 로고    scopus 로고
    • All-trans-retinoic acid: A phase II radiation therapy oncology group study (RTOG 91-13) in patients with recurrent malignant astrocytoma
    • 67 Phuphanich S., Scott C., Fischbach A. J., Langer C. and Yung W. K. (1997) All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. J. Neurooncol. 34: 193-200
    • (1997) J. Neurooncol. , vol.34 , pp. 193-200
    • Phuphanich, S.1    Scott, C.2    Fischbach, A.J.3    Langer, C.4    Yung, W.K.5
  • 68
    • 0026672032 scopus 로고
    • The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: Preliminary results in a series of "failed" patients
    • 68 Vertosick F. T. Jr, Selker R. G., Pollack I. F, and Arena V. (1992) The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of "failed" patients. Neurosurgery 30: 897-902
    • (1992) Neurosurgery , vol.30 , pp. 897-902
    • Vertosick F.T., Jr.1    Selker, R.G.2    Pollack, I.F.3    Arena, V.4
  • 70
    • 0000414874 scopus 로고    scopus 로고
    • Randomized trial of temodar® (TEM) versus procarbazine (PCB) in glioblastoma multiforme at first relapse
    • 70 Yung A., Levin V., Albright R., Olson J., Fredericks R., Fink K. et al. (1998) Randomized trial of Temodar® (TEM) versus procarbazine (PCB) in glioblastoma multiforme at first relapse. J. Neurooncol. 39: 102
    • (1998) J. Neurooncol. , vol.39 , pp. 102
    • Yung, A.1    Levin, V.2    Albright, R.3    Olson, J.4    Fredericks, R.5    Fink, K.6
  • 73
    • 17744402925 scopus 로고    scopus 로고
    • Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximinein human malignant glioma cells: The role of bcl-2
    • 73 Reber U., Wüllner U., Trepel M., Baumgart J., Seyfried J., Klockgether T. et al. (1998) Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximinein human malignant glioma cells: the role of bcl-2. Biochem. Pharmacol. 55: 349-359
    • (1998) Biochem. Pharmacol. , vol.55 , pp. 349-359
    • Reber, U.1    Wüllner, U.2    Trepel, M.3    Baumgart, J.4    Seyfried, J.5    Klockgether, T.6
  • 75
    • 0026591763 scopus 로고
    • A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma
    • 75 Shapiro W. R., Green S. B., Burger P. C., Selker R. G., VanGilder J. C., Robertson J. T. et al. (1992) A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J. Neurosurg. 76: 772-781
    • (1992) J. Neurosurg. , vol.76 , pp. 772-781
    • Shapiro, W.R.1    Green, S.B.2    Burger, P.C.3    Selker, R.G.4    VanGilder, J.C.5    Robertson, J.T.6
  • 77
    • 0028917333 scopus 로고
    • Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
    • 77 Brem H., Piantadosi S., Burger P. C., Walker M., Selker R., Vick N. A. et al. (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345: 1008-1012
    • (1995) Lancet , vol.345 , pp. 1008-1012
    • Brem, H.1    Piantadosi, S.2    Burger, P.C.3    Walker, M.4    Selker, R.5    Vick, N.A.6
  • 78
    • 0029582768 scopus 로고
    • The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I trial
    • 78 Brem H., Ewend M. G., Piantadosi S., Greenhoot J., Burger P. C. and Sisti M. (1995) The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J. Neurooncol. 26: 111-123
    • (1995) J. Neurooncol. , vol.26 , pp. 111-123
    • Brem, H.1    Ewend, M.G.2    Piantadosi, S.3    Greenhoot, J.4    Burger, P.C.5    Sisti, M.6
  • 79
    • 0026438269 scopus 로고
    • Neoadjuvant chemotherapy in the treatment of recurrent glioblastomas (GBM)
    • 79 Boiardi A., Silvani A., Croci D., Perego E. and Solero C. L. (1992) Neoadjuvant chemotherapy in the treatment of recurrent glioblastomas (GBM). Ital. J. Neurol. Sci. 13: 583-588
    • (1992) Ital. J. Neurol. Sci. , vol.13 , pp. 583-588
    • Boiardi, A.1    Silvani, A.2    Croci, D.3    Perego, E.4    Solero, C.L.5
  • 81
    • 0026598909 scopus 로고
    • Immunotoxins and central nervous system neoplasia
    • 81 Hall W. A. and Fodstad O. (1992) Immunotoxins and central nervous system neoplasia. J. Neurosurg. 76: 1-12
    • (1992) J. Neurosurg. , vol.76 , pp. 1-12
    • Hall, W.A.1    Fodstad, O.2
  • 82
    • 0028273552 scopus 로고
    • Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice
    • 82 Laske D. W., Ilercil O., Akbasak A., Youle R. J. and Oldfield E. H. (1994) Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J. Neurosurg. 80: 520-526
    • (1994) J. Neurosurg. , vol.80 , pp. 520-526
    • Laske, D.W.1    Ilercil, O.2    Akbasak, A.3    Youle, R.J.4    Oldfield, E.H.5
  • 83
    • 7144261725 scopus 로고    scopus 로고
    • The class III variant of the epidermal growth factor receptor (EGFRvIII): Characterization and utilization as an immunotherapeutic: Target
    • 83 Wikstrand C. J., Reist C. J., Archer G. E., Zalutsky M. R. and Bigner D. D. (1998) The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic: target. J. Neurovirol. 4: 148-158
    • (1998) J. Neurovirol. , vol.4 , pp. 148-158
    • Wikstrand, C.J.1    Reist, C.J.2    Archer, G.E.3    Zalutsky, M.R.4    Bigner, D.D.5
  • 84
    • 0028176650 scopus 로고
    • T-cell based cancer immunotherapy: Direct or redirected tumor-cell recognition?
    • 84 Beun G. D., Velde C. J. van de and Fleuren G. J. (1994) T-cell based cancer immunotherapy: direct or redirected tumor-cell recognition? Immunol. Today 15: 11-15
    • (1994) Immunol. Today , vol.15 , pp. 11-15
    • Beun, G.D.1    Van De Velde, C.J.2    Fleuren, G.J.3
  • 85
    • 0025161953 scopus 로고
    • Preliminary trial of specific targeting therapy against malignant glioma
    • 85 Nitta T., Sato K., Yagita H., Okumura K. and Ishii S. (1990) Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335: 368-371
    • (1990) Lancet , vol.335 , pp. 368-371
    • Nitta, T.1    Sato, K.2    Yagita, H.3    Okumura, K.4    Ishii, S.5
  • 86
    • 0023918761 scopus 로고
    • Immunoregulatory effects of interleukin 2 and interferon on syngeneie murine malignant glioma-specific cytotoxic T-lymphocytes
    • 86 Yamasaki T., Kikuchi H., Yamashita J., Handa H., Kuwata S., Taguchi M. et al. (1988) Immunoregulatory effects of interleukin 2 and interferon on syngeneie murine malignant glioma-specific cytotoxic T-lymphocytes. Cancer Res. 48: 2981-2987
    • (1988) Cancer Res. , vol.48 , pp. 2981-2987
    • Yamasaki, T.1    Kikuchi, H.2    Yamashita, J.3    Handa, H.4    Kuwata, S.5    Taguchi, M.6
  • 87
    • 0030844836 scopus 로고    scopus 로고
    • Neurotoxic consequences of central long-term administration of interleukin-2 in rats
    • 87 Hanisch U. K., Neuhaus J., Rowe W., Van Rossum D., Moller T., Kettenmann H. et al. (1997) Neurotoxic consequences of central long-term administration of interleukin-2 in rats. Neuroscience 79: 799-818
    • (1997) Neuroscience , vol.79 , pp. 799-818
    • Hanisch, U.K.1    Neuhaus, J.2    Rowe, W.3    Van Rossum, D.4    Moller, T.5    Kettenmann, H.6
  • 88
    • 0029145309 scopus 로고
    • Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma
    • 88 Hayes R. L., Koslow M., Hiesiger E. M., Hymes K. B., Hochster H. S., Moore E. J. et al. (1995) Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76: 840-852
    • (1995) Cancer , vol.76 , pp. 840-852
    • Hayes, R.L.1    Koslow, M.2    Hiesiger, E.M.3    Hymes, K.B.4    Hochster, H.S.5    Moore, E.J.6
  • 89
    • 0025745414 scopus 로고
    • Modulation of T-cell function by gliomas
    • 89 Roszman T., Elliott L. and Brooks W. (1991) Modulation of T-cell function by gliomas. Immunol. Today 12: 370-374
    • (1991) Immunol. Today , vol.12 , pp. 370-374
    • Roszman, T.1    Elliott, L.2    Brooks, W.3
  • 90
    • 0025000864 scopus 로고
    • Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity
    • 90 Gansbacher B., Zier K., Daniels B., Cronin K., Bannerji R. and Gilboa E. (1990) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172: 1217-1224
    • (1990) J. Exp. Med. , vol.172 , pp. 1217-1224
    • Gansbacher, B.1    Zier, K.2    Daniels, B.3    Cronin, K.4    Bannerji, R.5    Gilboa, E.6
  • 91
    • 0028218528 scopus 로고
    • In vivo transfer of the human interleukin-2 gene: Negative tumoricidal results in experimental brain tumors
    • 91 Ram Z., Walbridge S., Heiss J. D., Culver K. W., Blaese R. M. and Oldfield E. H. (1994) In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. J. Neurosurg. 80: 535-540
    • (1994) J. Neurosurg. , vol.80 , pp. 535-540
    • Ram, Z.1    Walbridge, S.2    Heiss, J.D.3    Culver, K.W.4    Blaese, R.M.5    Oldfield, E.H.6
  • 92
    • 0028907313 scopus 로고
    • Rg-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-γ
    • 92 Tjuvajev J., Gansbacher B., Desai R., Beattie B., Kaplitt M., Matci C. et al. (1995) RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-γ. Cancer Res. 55: 1902-1910
    • (1995) Cancer Res. , vol.55 , pp. 1902-1910
    • Tjuvajev, J.1    Gansbacher, B.2    Desai, R.3    Beattie, B.4    Kaplitt, M.5    Matci, C.6
  • 93
    • 0029865486 scopus 로고    scopus 로고
    • Eradication of established intracranial rat gliomas by transforming growth factor beta anti-sense gene therapy
    • 93 Fakhrai H., Dorigo O., Shawler D. L., Lin H., Mercola D., Black K. L, et al. (1996) Eradication of established intracranial rat gliomas by transforming growth factor beta anti-sense gene therapy. Proc. Natl. Acad. Sci. USA 93: 2909-2914
    • (1996) Proc. Natl. Acad. Sci. USA , vol.93 , pp. 2909-2914
    • Fakhrai, H.1    Dorigo, O.2    Shawler, D.L.3    Lin, H.4    Mercola, D.5    Black, K.L.6
  • 94
    • 0026581987 scopus 로고
    • Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1
    • 94 Inge T. H., Hoover S. K., Susskind B. M., Barrett S. K. and Bear H. D. (1992) Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Cancer Res. 52: 1386-1392
    • (1992) Cancer Res. , vol.52 , pp. 1386-1392
    • Inge, T.H.1    Hoover, S.K.2    Susskind, B.M.3    Barrett, S.K.4    Bear, H.D.5
  • 96
    • 0028217047 scopus 로고
    • Nervous tissue as an immune compartment: The dialect of the immune response in the CNS
    • 96 Fabry Z., Raine C. S. and Hart M. N. (1994) Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. Immunol. Today 15: 218-224
    • (1994) Immunol. Today , vol.15 , pp. 218-224
    • Fabry, Z.1    Raine, C.S.A.2    Hart, M.N.3
  • 97
    • 0027320628 scopus 로고
    • Inhibition of interferon-γ-induced major histocompatibility complex class II gene transcription by interferon-beta and type beta 1 transforming growth factor in human astrocyloma cells: Definition of cis-element
    • 97 Devajyothi C., Kalvakolanu I., Babcock G. T., Vasavada H. A., Howe P. H. and Ransohoff R. M. (1993) Inhibition of interferon-γ-induced major histocompatibility complex class II gene transcription by interferon-beta and type beta 1 transforming growth factor in human astrocyloma cells: definition of cis-element. J. Biol. Chem. 268: 18794-18800
    • (1993) J. Biol. Chem. , vol.268 , pp. 18794-18800
    • Devajyothi, C.1    Kalvakolanu, I.2    Babcock, G.T.3    Vasavada, H.A.4    Howe, P.H.5    Ransohoff, R.M.6
  • 98
    • 0023760336 scopus 로고
    • Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells
    • 98 Zuber P., Kuppner M. C. and Tribolet N. de (1988) Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells. Eur. J. Immunol. 18: 1623-1626
    • (1988) Eur. J. Immunol. , vol.18 , pp. 1623-1626
    • Zuber, P.1    Kuppner, M.C.2    De Tribolet, N.3
  • 99
    • 0026546822 scopus 로고
    • Effects of γ-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: Implications for strategies of immunotherapy
    • 99 Wen P. Y., Lampson M. A. and Lampson L. A. (1992) Effects of γ-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy. J. Neuroimmunol. 36: 57-68
    • (1992) J. Neuroimmunol. , vol.36 , pp. 57-68
    • Wen, P.Y.1    Lampson, M.A.2    Lampson, L.A.3
  • 100
    • 0032506347 scopus 로고    scopus 로고
    • IFNγ inhibition of cell growth in glioblastomas correlates with increased levels of the eyelin dependent kinase inhibitor p21WAF1/CIP1
    • 100 Kominsky S., Johnson H. M., Bryan G., Tanabe T., Hobeika A. C., Subramaniam P. S. et al. (1998) IFNγ inhibition of cell growth in glioblastomas correlates with increased levels of the eyelin dependent kinase inhibitor p21WAF1/CIP1. Oncogene 17: 2973-2979
    • (1998) Oncogene , vol.17 , pp. 2973-2979
    • Kominsky, S.1    Johnson, H.M.2    Bryan, G.3    Tanabe, T.4    Hobeika, A.C.5    Subramaniam, P.S.6
  • 101
    • 0028275672 scopus 로고
    • Randomised, controlled study of intratumoral recombinant γ-interferon treatment in newly diagnosed glioblastoma
    • 101 Färkkila M., Jaaskelainen J., Kallio M., Blomstedt G., Raininko R., Virkkunen P. et al. (1994) Randomised, controlled study of intratumoral recombinant γ-interferon treatment in newly diagnosed glioblastoma. Br. J. Cancer 70: 138-141
    • (1994) Br. J. Cancer , vol.70 , pp. 138-141
    • Färkkila, M.1    Jaaskelainen, J.2    Kallio, M.3    Blomstedt, G.4    Raininko, R.5    Virkkunen, P.6
  • 102
    • 0025741380 scopus 로고
    • The effects of local and systemic interferon beta (Fiblaferon) on supratentorial malignant cerebral glioma a phase II study
    • 102 Wild K. R. von and Knocke T. H. (1991) The effects of local and systemic interferon beta (Fiblaferon) on supratentorial malignant cerebral glioma a phase II study. Neurosurg. Rev. 14: 203-213
    • (1991) Neurosurg. Rev. , vol.14 , pp. 203-213
    • Von Wild, K.R.1    Knocke, T.H.2
  • 103
    • 0025945333 scopus 로고
    • Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: A phase I/II study
    • 103 Yung W. K., Prados M., Levin V. A., Fetell M. R., Bennett J., Mahaley M. S. et al. (1991) Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J. Clin. Oncol. 9: 1945-1949
    • (1991) J. Clin. Oncol. , vol.9 , pp. 1945-1949
    • Yung, W.K.1    Prados, M.2    Levin, V.A.3    Fetell, M.R.4    Bennett, J.5    Mahaley, M.S.6
  • 105
    • 0028177049 scopus 로고
    • Tumour necrosis factor-α induces an increase in susceptibility of human glioblastoma U87-MG cells to natural killer cell-mediated lysis
    • 105 Kondo S., Yin D., Takeuchi J., Morimura T., Miyatake S. I., Nakatsu S. et al. (1994) Tumour necrosis factor-α induces an increase in susceptibility of human glioblastoma U87-MG cells to natural killer cell-mediated lysis. Br. J. Cancer 69: 627-632
    • (1994) Br. J. Cancer , vol.69 , pp. 627-632
    • Kondo, S.1    Yin, D.2    Takeuchi, J.3    Morimura, T.4    Miyatake, S.I.5    Nakatsu, S.6
  • 106
    • 0028206935 scopus 로고
    • Liposomal transfection of human γ-interferon gene into human glioma cells and adoptive immunotherapy using lymphokine-activated killer cells
    • 106 Mizuno M., Yoshida J., Takaoka T. and Sugita K. (1994) Liposomal transfection of human γ-interferon gene into human glioma cells and adoptive immunotherapy using lymphokine-activated killer cells. J. Neurosurg. 80: 510-514
    • (1994) J. Neurosurg. , vol.80 , pp. 510-514
    • Mizuno, M.1    Yoshida, J.2    Takaoka, T.3    Sugita, K.4
  • 107
    • 0024320829 scopus 로고
    • Intratumoural injection of autologous lymphocytes plus human lymphoblastoid interferon for the treatment of glioblasltoma
    • 107 Vaquero J., Martinez R., Oya S., Coca S., Barbolla L., Ramiro J. et al. (1989) Intratumoural injection of autologous lymphocytes plus human lymphoblastoid interferon for the treatment of glioblasltoma. Acta Neurochir. Wien 98: 35-41
    • (1989) Acta Neurochir. Wien , vol.98 , pp. 35-41
    • Vaquero, J.1    Martinez, R.2    Oya, S.3    Coca, S.4    Barbolla, L.5    Ramiro, J.6
  • 108
    • 0027990763 scopus 로고
    • Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells:Induction and modulation of sensitivity by cytokines
    • 108 Weller M., Frei K., Groscurth P., Krammer P. H., Yonekawa Y. and Fontana A. (1994) Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells:induction and modulation of sensitivity by cytokines. J. Clin. Invest. 94: 954-964
    • (1994) J. Clin. Invest. , vol.94 , pp. 954-964
    • Weller, M.1    Frei, K.2    Groscurth, P.3    Krammer, P.H.4    Yonekawa, Y.5    Fontana, A.6
  • 109
    • 0032127022 scopus 로고    scopus 로고
    • Interferon-α enhances CD95L-induced apoptosis of human malignant glioma cells
    • 109 Roth W., Wagenknecht B., Dichgans J. and Weller M. (1998) Interferon-α enhances CD95L-induced apoptosis of human malignant glioma cells. J. Neuroimmunol. 87: 121-129
    • (1998) J. Neuroimmunol. , vol.87 , pp. 121-129
    • Roth, W.1    Wagenknecht, B.2    Dichgans, J.3    Weller, M.4
  • 110
    • 0031973358 scopus 로고    scopus 로고
    • Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: Association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest
    • 110 Roth W., Wagenknecht B., Grimmel C., Dichgans J. and Weller M. (1998) Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest. Br. J. Cancer 77: 404-411
    • (1998) Br. J. Cancer , vol.77 , pp. 404-411
    • Roth, W.1    Wagenknecht, B.2    Grimmel, C.3    Dichgans, J.4    Weller, M.5
  • 111
    • 0027518307 scopus 로고
    • Differential effects of tumor necrosis factor-α on proliferation, cell surface antigen expression, and cytokine interactions in malignant gliomas
    • 111 Chen T. C., Hinton D. R., Apuzzo M. L. and Hofman F. M. (1993) Differential effects of tumor necrosis factor-α on proliferation, cell surface antigen expression, and cytokine interactions in malignant gliomas. Neurosurgery 32: 85-94
    • (1993) Neurosurgery , vol.32 , pp. 85-94
    • Chen, T.C.1    Hinton, D.R.2    Apuzzo, M.L.3    Hofman, F.M.4
  • 112
    • 0026665652 scopus 로고
    • Clinical effect of intra-arterial tumor necrosis factor-α for malignant glioma
    • 112 Yoshida J., Wakabayashi T., Mizuno M., Sugita K., Yoshida T., Hori S. et al. (1992) Clinical effect of intra-arterial tumor necrosis factor-α for malignant glioma. J. Neurosurg. 77: 78-83
    • (1992) J. Neurosurg. , vol.77 , pp. 78-83
    • Yoshida, J.1    Wakabayashi, T.2    Mizuno, M.3    Sugita, K.4    Yoshida, T.5    Hori, S.6
  • 113
    • 0027439474 scopus 로고
    • Reinforced cytotoxicity of lymphokine-activated killer cells toward glioma cells by transfection with the tumor necrosis factor-α gene
    • 113 Tashiro T., Yoshida J., Mizuno M. and Sugita K. (1993) Reinforced cytotoxicity of lymphokine-activated killer cells toward glioma cells by transfection with the tumor necrosis factor-α gene. J. Neurosurg. 78: 252-256
    • (1993) J. Neurosurg. , vol.78 , pp. 252-256
    • Tashiro, T.1    Yoshida, J.2    Mizuno, M.3    Sugita, K.4
  • 114
    • 0027296846 scopus 로고
    • Modulation of proliferation and antigen expression of a cloned human glioblastoma by interleukin-4 alone and in combination with tumor necrosis factor-α and/or interferon-γ
    • 114 Iwasaki K., Rogers L. R., Estes M. L. and Barna B. P. (1993) Modulation of proliferation and antigen expression of a cloned human glioblastoma by interleukin-4 alone and in combination with tumor necrosis factor-α and/or interferon-γ. Neurosurgery 33: 489-493
    • (1993) Neurosurgery , vol.33 , pp. 489-493
    • Iwasaki, K.1    Rogers, L.R.2    Estes, M.L.3    Barna, B.P.4
  • 115
    • 0026657391 scopus 로고
    • An cosinophil-dependent mechanism for the antitumor effect of interleukin-4
    • 115 Tepper R. I., Coffman R. L. and Leder P. (1992) An cosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257: 548-551
    • (1992) Science , vol.257 , pp. 548-551
    • Tepper, R.I.1    Coffman, R.L.2    Leder, P.3
  • 116
    • 0027203715 scopus 로고
    • Treatment of glioma by engineered interleukin 4-secreting cells
    • 116 Yu J. S., Wei M. X., Chiocca E. A., Martuza R. L. and Tepper R. I. (1993) Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res. 53: 3125-3128
    • (1993) Cancer Res. , vol.53 , pp. 3125-3128
    • Yu, J.S.1    Wei, M.X.2    Chiocca, E.A.3    Martuza, R.L.4    Tepper, R.I.5
  • 117
    • 0026645274 scopus 로고
    • Sensitivity of human glioma and brain cells to natural killer cell lysis. Effects of serum concentration, epidermal growth factor, and time in culture
    • 117 Myers R. L., Whisler R. L., Stephens R. E., Sponseller C. A., Livingston K., Spring P. M. et al. (1992) Sensitivity of human glioma and brain cells to natural killer cell lysis. Effects of serum concentration, epidermal growth factor, and time in culture. J. Neurosurg. 76: 986-990
    • (1992) J. Neurosurg. , vol.76 , pp. 986-990
    • Myers, R.L.1    Whisler, R.L.2    Stephens, R.E.3    Sponseller, C.A.4    Livingston, K.5    Spring, P.M.6
  • 120
    • 0028108663 scopus 로고
    • Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients
    • 120 Boiardi A., Silvani A., Ruffini P. A., Rivoltini L., Parmiani G., Broggi G. et al. (1994) Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol. Immunother. 39: 193-197
    • (1994) Cancer Immunol. Immunother. , vol.39 , pp. 193-197
    • Boiardi, A.1    Silvani, A.2    Ruffini, P.A.3    Rivoltini, L.4    Parmiani, G.5    Broggi, G.6
  • 121
    • 0022641036 scopus 로고
    • Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: Phase I trial
    • 121 Jacobs S. K., Wilson D. J., Kornblith P. L. and Grimm E. A. (1986) Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res. 46: 2101-2104
    • (1986) Cancer Res. , vol.46 , pp. 2101-2104
    • Jacobs, S.K.1    Wilson, D.J.2    Kornblith, P.L.3    Grimm, E.A.4
  • 122
    • 0027314032 scopus 로고
    • Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes. I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA
    • 122 Jeffes E. W. 3rd, Beamer Y. B., Jacques S., Silberman R. S., Vayuvegula B., Gupta S. et al. (1993) Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes. I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA. J. Neurooncol. 15: 141-155
    • (1993) J. Neurooncol. , vol.15 , pp. 141-155
    • Jeffes E.W. III1    Beamer, Y.B.2    Jacques, S.3    Silberman, R.S.4    Vayuvegula, B.5    Gupta, S.6
  • 123
    • 0025974603 scopus 로고
    • Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy
    • 123 Lillehei K. O., Mitchell D. H., Johnson S. D., McCleary E. L. and Kruse C. A. (1991) Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 28: 16-23
    • (1991) Neurosurgery , vol.28 , pp. 16-23
    • Lillehei, K.O.1    Mitchell, D.H.2    Johnson, S.D.3    McCleary, E.L.4    Kruse, C.A.5
  • 124
    • 0024210594 scopus 로고
    • Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor
    • 124 Merchant R. E., Merchant L. H., Cook S. H., McVicar D. W. and Young H. F. (1988) Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 23: 725-732
    • (1988) Neurosurgery , vol.23 , pp. 725-732
    • Merchant, R.E.1    Merchant, L.H.2    Cook, S.H.3    McVicar, D.W.4    Young, H.F.5
  • 125
    • 0030065695 scopus 로고    scopus 로고
    • Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors
    • 125 Sankhla S. K., Nadkarni J. S. and Bhagwati S. N. (1996) Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J. Neurooncol. 27: 133-140
    • (1996) J. Neurooncol. , vol.27 , pp. 133-140
    • Sankhla, S.K.1    Nadkarni, J.S.2    Bhagwati, S.N.3
  • 126
    • 0028885277 scopus 로고
    • Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors
    • 126 Nakagawa K., Kamezaki T., Shibata Y., Tsunoda T., Meguro K. and Nose T. (1995) Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors. Neurol. Med. Chir. Tokyo. 35: 22-27
    • (1995) Neurol. Med. Chir. Tokyo. , vol.35 , pp. 22-27
    • Nakagawa, K.1    Kamezaki, T.2    Shibata, Y.3    Tsunoda, T.4    Meguro, K.5    Nose, T.6
  • 127
    • 0026521970 scopus 로고
    • Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes
    • 127 Saris S. C., Spiess P., Lieberman D. M., Lin S., Walbridge S. and Oldfield E. H. (1992) Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J. Neurosurg. 76: 513-519
    • (1992) J. Neurosurg. , vol.76 , pp. 513-519
    • Saris, S.C.1    Spiess, P.2    Lieberman, D.M.3    Lin, S.4    Walbridge, S.5    Oldfield, E.H.6
  • 128
    • 0027155436 scopus 로고
    • Cancer vaccines
    • 128 Pardoll D. M. (1993) Cancer vaccines. Immunol. Today 14: 310-316
    • (1993) Immunol. Today , vol.14 , pp. 310-316
    • Pardoll, D.M.1
  • 129
    • 0028318967 scopus 로고
    • The effect of irradiation on expression of HLA class I antigens in human brain tumors in culture
    • 129 Klein B., Loven D., Lurie H., Rakowsky E., Nyska A., Levin I. et al. (1994) The effect of irradiation on expression of HLA class I antigens in human brain tumors in culture. J. Neurosurg. 80: 1074-1077
    • (1994) J. Neurosurg. , vol.80 , pp. 1074-1077
    • Klein, B.1    Loven, D.2    Lurie, H.3    Rakowsky, E.4    Nyska, A.5    Levin, I.6
  • 130
    • 0025984468 scopus 로고
    • Expression of MHC class II antigens on human glioma cells modulated by transfection with genes encoding these antigens
    • 130 Yoshida S., Takahashi H. and Tanaka R. (1991) Expression of MHC class II antigens on human glioma cells modulated by transfection with genes encoding these antigens. Neurol. Med. Chir. Tokyo. 31: 623-628
    • (1991) Neurol. Med. Chir. Tokyo. , vol.31 , pp. 623-628
    • Yoshida, S.1    Takahashi, H.2    Tanaka, R.3
  • 131
    • 0027394642 scopus 로고
    • Vaccinations with tumor cells genetically engineered to produce different cytokines: Effectivity not superior to a classical adjuvant
    • 131 Hock H., Dorsch M., Kunzendorf U., Uberla K., Qin Z., Diamantstein T. et al. (1993) Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res. 53: 714-716
    • (1993) Cancer Res. , vol.53 , pp. 714-716
    • Hock, H.1    Dorsch, M.2    Kunzendorf, U.3    Uberla, K.4    Qin, Z.5    Diamantstein, T.6
  • 132
    • 0030854533 scopus 로고    scopus 로고
    • Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells
    • 132 Yu J. S., Burwick J. A., Dranoff G. and Breakefield X. O. (1997) Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum. Gene Ther. 8: 1065-1072
    • (1997) Hum. Gene Ther. , vol.8 , pp. 1065-1072
    • Yu, J.S.1    Burwick, J.A.2    Dranoff, G.3    Breakefield, X.O.4
  • 133
    • 0028967430 scopus 로고
    • Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy?
    • 133 Grabbe S., Beissert S., Schwarz, T. and Granstein R. D. (1995) Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol. Today 16: 117-121
    • (1995) Immunol. Today , vol.16 , pp. 117-121
    • Grabbe, S.1    Beissert, S.2    Schwarz, T.3    Granstein, R.D.4
  • 135
    • 0030034580 scopus 로고    scopus 로고
    • Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/ IV astrocytoma
    • 135 Holladay F. P., Heitz Turner T., Bayer W. L. and Wood G. W. (1996) Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/ IV astrocytoma. J. Neurooncol. 27: 179-189
    • (1996) J. Neurooncol. , vol.27 , pp. 179-189
    • Holladay, F.P.1    Heitz Turner, T.2    Bayer, W.L.3    Wood, G.W.4
  • 136
    • 0028813149 scopus 로고
    • Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen
    • 136 Treisman J., Hwu P., Minamoto S., Shafer G. E., Cowherd R., Morgan R. A. et al. (1995) Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood 85: 139-145
    • (1995) Blood , vol.85 , pp. 139-145
    • Treisman, J.1    Hwu, P.2    Minamoto, S.3    Shafer, G.E.4    Cowherd, R.5    Morgan, R.A.6
  • 137
    • 0032893390 scopus 로고    scopus 로고
    • TGF-β and p21: Multiple molecular targets of decorin-mediated suppression of neoplastic growth
    • 137 Ständer M., Naumann U., Wick W. and Weller M. (1999) TGF-β and p21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res. 296: 221-227
    • (1999) Cell Tissue Res. , vol.296 , pp. 221-227
    • Ständer, M.1    Naumann, U.2    Wick, W.3    Weller, M.4
  • 138
    • 0024390026 scopus 로고
    • Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo
    • 138 Krosnick J. A., Mulé J. J., McIntosh J. K. and Rosenberg S. A. (1989) Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res. 49: 3729-3733
    • (1989) Cancer Res. , vol.49 , pp. 3729-3733
    • Krosnick, J.A.1    Mulé, J.J.2    McIntosh, J.K.3    Rosenberg, S.A.4
  • 139
    • 0028970787 scopus 로고
    • Interferon-alpha or beta potentiate platinum analogous in human glioblastoma cell lines
    • 139 Stanzione S., Cimoli G., Debernardis D., Michelotti A., Conte P., Parodi S. et al. (1995) Interferon-alpha or beta potentiate platinum analogous in human glioblastoma cell lines. Mutat. Res. 348: 131-135
    • (1995) Mutat. Res. , vol.348 , pp. 131-135
    • Stanzione, S.1    Cimoli, G.2    Debernardis, D.3    Michelotti, A.4    Conte, P.5    Parodi, S.6
  • 140
    • 0030896574 scopus 로고    scopus 로고
    • Immunochemotherapy of malignant glioma: Synergistic activity of CD95 ligand and chemotherapeutics
    • 140 Roth W., Fontana A., Trepel M., Reed J. C., Dichgans J. and Weller M. (1997) Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol. Immunother. 44: 55-63
    • (1997) Cancer Immunol. Immunother. , vol.44 , pp. 55-63
    • Roth, W.1    Fontana, A.2    Trepel, M.3    Reed, J.C.4    Dichgans, J.5    Weller, M.6
  • 141
  • 142
  • 143
    • 0029820016 scopus 로고    scopus 로고
    • Activation of the CPP32protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents
    • 143 Datta R., Banach D., Kojima H., Talanian R. V., Alnemri E. S., Wong W. W. et al. (1996) Activation of the CPP32protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood 88: 1936-1943
    • (1996) Blood , vol.88 , pp. 1936-1943
    • Datta, R.1    Banach, D.2    Kojima, H.3    Talanian, R.V.4    Alnemri, E.S.5    Wong, W.W.6
  • 144
    • 0029007855 scopus 로고
    • The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation
    • 144 Hsu H., Xiong J. and Goeddel D. V. (1995) The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 81: 495-504
    • (1995) Cell , vol.81 , pp. 495-504
    • Hsu, H.1    Xiong, J.2    Goeddel, D.V.3
  • 145
    • 0032567912 scopus 로고    scopus 로고
    • Cellular responses to interferons and other cytokines: The JAK-STAT paradigm
    • 145 Ransohoff R. M. (1998) Cellular responses to interferons and other cytokines: the JAK-STAT paradigm. N. Engl. J. Med. 338: 616-618
    • (1998) N. Engl. J. Med. , vol.338 , pp. 616-618
    • Ransohoff, R.M.1
  • 147
    • 0030856633 scopus 로고    scopus 로고
    • Phase II trial with BCNU plus α-interferon in patients with recurrent high-grade gliomas
    • 147 Brandes A. A., Scelzi E., Zampieri P., Rigon A., Rotilio A., Amista P. et al. (1997) Phase II trial with BCNU plus α-interferon in patients with recurrent high-grade gliomas. Am. J. Clin. Oncol. 20: 364-367
    • (1997) Am. J. Clin. Oncol. , vol.20 , pp. 364-367
    • Brandes, A.A.1    Scelzi, E.2    Zampieri, P.3    Rigon, A.4    Rotilio, A.5    Amista, P.6
  • 149
    • 0031776472 scopus 로고    scopus 로고
    • Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma
    • 149 Buckner J. C., Burch P. A., Cascino T. L., O'Fallon J. R. and Scheithauer B. W. (1998) Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma. J. Neurooncol. 36: 65-70
    • (1998) J. Neurooncol. , vol.36 , pp. 65-70
    • Buckner, J.C.1    Burch, P.A.2    Cascino, T.L.3    O'Fallon, J.R.A.4    Scheithauer, B.W.5
  • 150
    • 0031950726 scopus 로고    scopus 로고
    • High dose oral tamoxifen and subcutaneous interferon α-2a for recurrent glioma
    • 150 Chang S. M., Barker F. G., Huhn S. L., Nicholas M. K., Page M., Rabbitt J. et al. (1998) High dose oral tamoxifen and subcutaneous interferon α-2a for recurrent glioma. J. Neurooncol. 37: 169-176
    • (1998) J. Neurooncol. , vol.37 , pp. 169-176
    • Chang, S.M.1    Barker, F.G.2    Huhn, S.L.3    Nicholas, M.K.4    Page, M.5    Rabbitt, J.6
  • 151
    • 0024531767 scopus 로고
    • Intratumor application of human leukocyte interferon-α in patients with malignant brain tumors
    • 151 Jereb B., Petric J., Lamovec J., Skrbec M. and Soss E. (1989) Intratumor application of human leukocyte interferon-α in patients with malignant brain tumors. Am. J. Clin. Oncol. 12: 1-7
    • (1989) Am. J. Clin. Oncol. , vol.12 , pp. 1-7
    • Jereb, B.1    Petric, J.2    Lamovec, J.3    Skrbec, M.4    Soss, E.5
  • 153
    • 0029014123 scopus 로고
    • Attempted dose intensified cyclophosphamide, etoposide, and granulocyte colony-stimulating factor for treatment of malignant astrocytoma
    • 153 Newton H. B. and Newton C. L. (1995) Attempted dose intensified cyclophosphamide, etoposide, and granulocyte colony-stimulating factor for treatment of malignant astrocytoma. J. Neurooncol. 24: 285-292
    • (1995) J. Neurooncol. , vol.24 , pp. 285-292
    • Newton, H.B.1    Newton, C.L.2
  • 155
    • 0025542982 scopus 로고
    • Intratumoral beta interferon and systemic chemotherapy: Preliminary data in GBM patients
    • 155 Silvani A., Milanesi I., Munari L., Broggi G., Botturi M. and Boiardi A. (1990) Intratumoral beta interferon and systemic chemotherapy: preliminary data in GBM patients. J. Neurosurg. Sci. 34: 257-259
    • (1990) J. Neurosurg. Sci. , vol.34 , pp. 257-259
    • Silvani, A.1    Milanesi, I.2    Munari, L.3    Broggi, G.4    Botturi, M.5    Boiardi, A.6
  • 156
    • 0028345187 scopus 로고
    • Long-term follow-up results of 175 patients with malignant glioma: Importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation
    • 156 Yoshida J., Kajita Y., Wakabayashi T. and Sugita K. (1994) Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir. Wien 127: 55-59
    • (1994) Acta Neurochir. Wien , vol.127 , pp. 55-59
    • Yoshida, J.1    Kajita, Y.2    Wakabayashi, T.3    Sugita, K.4
  • 158
    • 0020546765 scopus 로고
    • Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies
    • 158 Wikstrand C. J., Bigner S. H. and Bigner D. D. (1983) Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies. Cancer Res. 43: 3327-3334
    • (1983) Cancer Res. , vol.43 , pp. 3327-3334
    • Wikstrand, C.J.1    Bigner, S.H.2    Bigner, D.D.3
  • 160
    • 0030888267 scopus 로고    scopus 로고
    • Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas
    • 160 Black K. L., Cloughesy T., Huang S. C., Gobin Y. P., Zhou Y., Grous J. et al. (1997) Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J. Neurosurg. 86: 603-609
    • (1997) J. Neurosurg. , vol.86 , pp. 603-609
    • Black, K.L.1    Cloughesy, T.2    Huang, S.C.3    Gobin, Y.P.4    Zhou, Y.5    Grous, J.6
  • 161
    • 0032189111 scopus 로고    scopus 로고
    • A phase 1 study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma
    • 161 Ford J., Osborn C., Barton T. and Blechen N. M. (1998) A phase 1 study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur. J. Cancer 34: 1807-1811
    • (1998) Eur. J. Cancer , vol.34 , pp. 1807-1811
    • Ford, J.1    Osborn, C.2    Barton, T.3    Blechen, N.M.4
  • 162
    • 43949160470 scopus 로고
    • Inflammatory cytokines in the brain: Does the CNS shape immune responses?
    • 162 Owens T., Renno T., Taupin V. and Krakowski M. (1994) Inflammatory cytokines in the brain: does the CNS shape immune responses? Immunol. Today 15: 566-571
    • (1994) Immunol. Today , vol.15 , pp. 566-571
    • Owens, T.1    Renno, T.2    Taupin, V.3    Krakowski, M.4
  • 163
    • 0026582225 scopus 로고
    • Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo
    • 163 Aoki T., Tashiro K., Miyatake S., Kinashi T., Nakano T., Oda Y. et al. (1992) Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc. Natl. Acad. Sci. USA 89: 3850-3854
    • (1992) Proc. Natl. Acad. Sci. USA , vol.89 , pp. 3850-3854
    • Aoki, T.1    Tashiro, K.2    Miyatake, S.3    Kinashi, T.4    Nakano, T.5    Oda, Y.6
  • 164
    • 0027507179 scopus 로고
    • Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA
    • 164 Trojan J., Johnson T. R., Rudin S. D., Ilan J. and Tykocinski M. L. (1993) Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259: 94-97
    • (1993) Science , vol.259 , pp. 94-97
    • Trojan, J.1    Johnson, T.R.2    Rudin, S.D.3    Ilan, J.4    Tykocinski, M.L.5
  • 165
    • 0028271497 scopus 로고
    • Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors
    • 165 Resnicoff M., Sell C., Rubini M., Coppola D., Ambrose D., Baserga R. et al. (1994) Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res. 54: 2218-2222
    • (1994) Cancer Res. , vol.54 , pp. 2218-2222
    • Resnicoff, M.1    Sell, C.2    Rubini, M.3    Coppola, D.4    Ambrose, D.5    Baserga, R.6
  • 166
    • 0027979670 scopus 로고
    • Generation of cytotoxic immune responses during the progression of a rat glioma
    • 166 Holladay F. P., Choudhuri R., Heitz T. and Wood G. W. (1994) Generation of cytotoxic immune responses during the progression of a rat glioma. J. Neurosurg. 80: 90-96
    • (1994) J. Neurosurg. , vol.80 , pp. 90-96
    • Holladay, F.P.1    Choudhuri, R.2    Heitz, T.3    Wood, G.W.4
  • 168
    • 0024212342 scopus 로고
    • Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas
    • 168 Kuppner M. C., Hamou M. F. and Tribolet N. de (1988) Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas. Cancer Res. 48: 6926-6932
    • (1988) Cancer Res. , vol.48 , pp. 6926-6932
    • Kuppner, M.C.1    Hamou, M.F.2    De Tribolet, N.3
  • 169
    • 0023841573 scopus 로고
    • In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers
    • 169 Miescher S., Whiteside T. L., Tribolet N. de and Fliedner V. von (1988) In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J. Neurosurg. 68: 438-448
    • (1988) J. Neurosurg. , vol.68 , pp. 438-448
    • Miescher, S.1    Whiteside, T.L.2    De Tribolet, N.3    Von Fliedner, V.4
  • 170
    • 0029610610 scopus 로고
    • The failure of current immunotherapy for malignant glioma: Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain
    • 170 Weller M. and Fontana A. (1995) The failure of current immunotherapy for malignant glioma: tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res. Rev. 21: 128-151
    • (1995) Brain Res. Rev. , vol.21 , pp. 128-151
    • Weller, M.1    Fontana, A.2
  • 171
    • 0026667037 scopus 로고
    • Inflammatory leukocytes associated with increased immuno-suppression by glioblastoma
    • 171 Black K. L., Chen K., Becker D. P. and Merrill J. E. (1992) Inflammatory leukocytes associated with increased immuno-suppression by glioblastoma. J. Neurosurg. 77: 120-126
    • (1992) J. Neurosurg. , vol.77 , pp. 120-126
    • Black, K.L.1    Chen, K.2    Becker, D.P.3    Merrill, J.E.4
  • 172
    • 0026093652 scopus 로고
    • Modulation of human leukocyte antigenDR expression in glioblastoma cells by interferon γ and other cytokines
    • 172 Hong L. L., Johannsen L. and Krueger J. M. (1991) Modulation of human leukocyte antigenDR expression in glioblastoma cells by interferon γ and other cytokines. J. Neuroimmunol. 35: 139-152
    • (1991) J. Neuroimmunol. , vol.35 , pp. 139-152
    • Hong, L.L.1    Johannsen, L.2    Krueger, J.M.3
  • 173
    • 0028178471 scopus 로고
    • Transforming growth factor-beta 2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression
    • 173 Weller M., Constam D. B., Malipiero U. and Fontana A. (1994) Transforming growth factor-beta 2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. Eur. J. Immunol. 24: 1293-1300
    • (1994) Eur. J. Immunol. , vol.24 , pp. 1293-1300
    • Weller, M.1    Constam, D.B.2    Malipiero, U.3    Fontana, A.4
  • 174
    • 0028980745 scopus 로고
    • TGF-beta 1 and cyclic AMP promote apoptosis in resting human B lymphocytes
    • 174 Lomo J., Blomhoff H. K., Beiske K., Stokke T. and Smeland E. B. (1995) TGF-beta 1 and cyclic AMP promote apoptosis in resting human B lymphocytes. J. Immunol. 154: 1634-1643
    • (1995) J. Immunol. , vol.154 , pp. 1634-1643
    • Lomo, J.1    Blomhoff, H.K.2    Beiske, K.3    Stokke, T.4    Smeland, E.B.5
  • 175
    • 0025895774 scopus 로고
    • TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: Evidence in support of an autocrine hypothesis
    • 175 Jennings M. T., Maciunas R. J., Carver R., Bascom C. C., Juneau P., Misulis K. et al. (1991) TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis. Int. J. Cancer 49: 129-139
    • (1991) Int. J. Cancer , vol.49 , pp. 129-139
    • Jennings, M.T.1    Maciunas, R.J.2    Carver, R.3    Bascom, C.C.4    Juneau, P.5    Misulis, K.6
  • 176
    • 0026712153 scopus 로고
    • Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: Validity of neutralizing antibodies to block tumor growth
    • 176 Ucki N., Nakazato M., Ohkawa T., Ikeda T., Amuro Y., Hada T. et al. (1992) Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim. Biophys. Acta 1137: 189-196
    • (1992) Biochim. Biophys. Acta , vol.1137 , pp. 189-196
    • Ucki, N.1    Nakazato, M.2    Ohkawa, T.3    Ikeda, T.4    Amuro, Y.5    Hada, T.6
  • 177
    • 0031698247 scopus 로고    scopus 로고
    • Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene
    • 177 Liau L. M., Fakhrai H. and Black K. L. (1998) Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene. Neurol. Res. 20: 742-747
    • (1998) Neurol. Res. , vol.20 , pp. 742-747
    • Liau, L.M.1    Fakhrai, H.2    Black, K.L.3
  • 178
    • 0027223428 scopus 로고
    • The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma
    • 178 Jachimczak P., Bogdahn U., Schneider J., Behl C., Meixensberger J., Apfel R. et al. (1993) The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J. Neurosurg. 78: 944-951
    • (1993) J. Neurosurg. , vol.78 , pp. 944-951
    • Jachimczak, P.1    Bogdahn, U.2    Schneider, J.3    Behl, C.4    Meixensberger, J.5    Apfel, R.6
  • 179
    • 0031717878 scopus 로고    scopus 로고
    • Decorin gene transfer-mediated suppression of TGF-β synthesis abrogates experimental malignant glioma growth in vivo
    • 179 Ständer M., Naumann U., Dumitrescu L., Heneka M., Löschmann P., Gulbins E. et al. (1998) Decorin gene transfer-mediated suppression of TGF-β synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther. 5: 1187-1194
    • (1998) Gene Ther. , vol.5 , pp. 1187-1194
    • Ständer, M.1    Naumann, U.2    Dumitrescu, L.3    Heneka, M.4    Löschmann, P.5    Gulbins, E.6
  • 180
    • 0026735230 scopus 로고
    • Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I
    • 180 Trojan J., Blossey B. K., Johnson T. R., Rudin S. D., Tykocinski M. and Ilan J. (1992) Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc. Natl. Acad. Sci. USA 89: 4874-4878
    • (1992) Proc. Natl. Acad. Sci. USA , vol.89 , pp. 4874-4878
    • Trojan, J.1    Blossey, B.K.2    Johnson, T.R.3    Rudin, S.D.4    Tykocinski, M.5    Ilan, J.6
  • 181
    • 0030889351 scopus 로고    scopus 로고
    • Curing rat glioblastoma: Immunotherapy or graft rejection?
    • 181 Beutler A. S., Banck M. S. and Aguzzi A. (1997) Curing rat glioblastoma: immunotherapy or graft rejection? Science 276: 20-21
    • (1997) Science , vol.276 , pp. 20-21
    • Beutler, A.S.1    Banck, M.S.2    Aguzzi, A.3
  • 183
    • 0025773050 scopus 로고
    • Malignant glioma modulation of immune function: Relative contribution of different soluble factors
    • 183 Couldwell W. T., Dore Duffy P., Apuzzo M. L. and Antel J. P. (1991) Malignant glioma modulation of immune function: relative contribution of different soluble factors. J. Neuroimmunol. 33: 89-96
    • (1991) J. Neuroimmunol. , vol.33 , pp. 89-96
    • Couldwell, W.T.1    Dore Duffy, P.2    Apuzzo, M.L.3    Antel, J.P.4
  • 184
    • 0020461752 scopus 로고
    • Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells
    • 184 Fontana A., Kristensen F., Dubs R., Gemsa D. and Weber E. (1982) Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J. Immunol. 129: 2413-2419
    • (1982) J. Immunol. , vol.129 , pp. 2413-2419
    • Fontana, A.1    Kristensen, F.2    Dubs, R.3    Gemsa, D.4    Weber, E.5
  • 185
    • 0025195323 scopus 로고
    • Influence of PGE2-and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes
    • 185 Kuppner M. C., Sawamura Y., Hamou M. E. and Tribolet N. de (1990) Influence of PGE2-and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes. J. Neurosurg. 72: 619-625
    • (1990) J. Neurosurg. , vol.72 , pp. 619-625
    • Kuppner, M.C.1    Sawamura, Y.2    Hamou, M.E.3    De Tribolet, N.4
  • 186
    • 0028807156 scopus 로고
    • Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro
    • 186 Hishii M., Nitta T., Ishida H., Ebato M., Kurosu A., Yagita H. et al. (1995) Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 37: 1160-1166
    • (1995) Neurosurgery , vol.37 , pp. 1160-1166
    • Hishii, M.1    Nitta, T.2    Ishida, H.3    Ebato, M.4    Kurosu, A.5    Yagita, H.6
  • 187
    • 0027998817 scopus 로고
    • In vitro studies of cytokine-mediated interactions between malignant glioma and autologous peripheral blood mononuclear cells
    • 187 Jachimezak P., Schwulera U. and Bogdahn U. (1994) In vitro studies of cytokine-mediated interactions between malignant glioma and autologous peripheral blood mononuclear cells. J. Neurosurg. 81: 579-586
    • (1994) J. Neurosurg. , vol.81 , pp. 579-586
    • Jachimezak, P.1    Schwulera, U.2    Bogdahn, U.3
  • 188
    • 0025933119 scopus 로고
    • Monocyte tumoricidal activity and tumor necrosis factor production in patients with malignant brain tumors
    • 188 Barna B. P., Rogers L. R., Thomassen M. J., Barnett G. H. and Estes M. L. (1991) Monocyte tumoricidal activity and tumor necrosis factor production in patients with malignant brain tumors. Cancer Immunol. Immunother. 33: 314-318
    • (1991) Cancer Immunol. Immunother. , vol.33 , pp. 314-318
    • Barna, B.P.1    Rogers, L.R.2    Thomassen, M.J.3    Barnett, G.H.4    Estes, M.L.5
  • 189
    • 0027935396 scopus 로고
    • Enhanced interleukin-1 beta release and longevity of glioma-associated peripheral blood monocytes in vitro
    • 189 Fries G., Perneczky A. and Kempski O. (1994) Enhanced interleukin-1 beta release and longevity of glioma-associated peripheral blood monocytes in vitro. Neurosurgery 35: 264-270
    • (1994) Neurosurgery , vol.35 , pp. 264-270
    • Fries, G.1    Perneczky, A.2    Kempski, O.3
  • 191
    • 0027276474 scopus 로고
    • The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas
    • 191 Rimoldi D., Romero P. and Carrel S. (1993) The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. Int. J. Cancer 54: 527-528
    • (1993) Int. J. Cancer , vol.54 , pp. 527-528
    • Rimoldi, D.1    Romero, P.2    Carrel, S.3
  • 193
    • 0028203254 scopus 로고
    • A mouse mutant p53 product recognized by CD4 + and CD8 + t cells
    • 193 Noguchi Y., Chen Y. T. and Old L. J. (1994) A mouse mutant p53 product recognized by CD4 + and CD8 + T cells. Proc. Natl. Acad. Sci. USA 91: 3171-3175
    • (1994) Proc. Natl. Acad. Sci. USA , vol.91 , pp. 3171-3175
    • Noguchi, Y.1    Chen, Y.T.2    Old, L.J.3
  • 194
    • 0021932240 scopus 로고
    • Amplification, enhanced expression and possible rearrangement of FGF receptor gene in primary human brain tumours of glial origin
    • 194 Libermann T. A., Nusbaum H. R., Razon N., Kris R., Lax I., Soreq H. et al. (1985) Amplification, enhanced expression and possible rearrangement of FGF receptor gene in primary human brain tumours of glial origin. Nature 313: 144-147
    • (1985) Nature , vol.313 , pp. 144-147
    • Libermann, T.A.1    Nusbaum, H.R.2    Razon, N.3    Kris, R.4    Lax, I.5    Soreq, H.6
  • 196
    • 0031464925 scopus 로고    scopus 로고
    • B7-1(CD80)-transfected human glioma cells and interleukin-12 directly stimulate allogeneic CD8 + T cells
    • 196 Komata T., Tanaka R., Yamamoto K., Oda T., Ono K., Yoshida S. et al. (1997) B7-1(CD80)-transfected human glioma cells and interleukin-12 directly stimulate allogeneic CD8 + T cells. J. Immunother. 20: 256-264
    • (1997) J. Immunother. , vol.20 , pp. 256-264
    • Komata, T.1    Tanaka, R.2    Yamamoto, K.3    Oda, T.4    Ono, K.5    Yoshida, S.6
  • 197
    • 0030743966 scopus 로고    scopus 로고
    • Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model
    • 197 Parney I. F., Petruk K. C., Zhang C., Farr Jones M., Sykes D. B. and Chang L. J. (1997) Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model. Hum. Gene Ther. 8: 1073-1085
    • (1997) Hum. Gene Ther. , vol.8 , pp. 1073-1085
    • Parney, I.F.1    Petruk, K.C.2    Zhang, C.3    Farr Jones, M.4    Sykes, D.B.5    Chang, L.J.6
  • 199
    • 0344938399 scopus 로고    scopus 로고
    • IL-1 beta inhibits IFN-γ-induced class II MHC expression by suppressing transcription of the class II transactivator gene
    • 199 Rohn W., Tang L. P., Dong Y. and Benveniste E. N. (1999) IL-1 beta inhibits IFN-γ-induced class II MHC expression by suppressing transcription of the class II transactivator gene. J. Immunol. 162: 886-896
    • (1999) J. Immunol. , vol.162 , pp. 886-896
    • Rohn, W.1    Tang, L.P.2    Dong, Y.3    Benveniste, E.N.4
  • 200
    • 0027937745 scopus 로고
    • Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
    • 200 Lowin B., Hahne M., Mattmann C. and Tschopp J. (1994) Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370: 650-652
    • (1994) Nature , vol.370 , pp. 650-652
    • Lowin, B.1    Hahne, M.2    Mattmann, C.3    Tschopp, J.4
  • 201
    • 0032435612 scopus 로고    scopus 로고
    • DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma
    • 201 Friedman H. S., McLendon R. E., Kerby T., Dugan M., Bigner S. H., Henry A. J. et al. (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J. Clin. Oncol. 16: 3851-3857
    • (1998) J. Clin. Oncol. , vol.16 , pp. 3851-3857
    • Friedman, H.S.1    McLendon, R.E.2    Kerby, T.3    Dugan, M.4    Bigner, S.H.5    Henry, A.J.6
  • 202
    • 0032008537 scopus 로고    scopus 로고
    • O6-methylguanine-DNA methyltransferase activity in adult gliomas: Relation to patient and tumor characteristics
    • 202 Silber J. R., Bobola M. S., Ghatan S., Blank A., Kolstoe D. D. and Berger M. S. (1998) O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res. 58: 1068-1073
    • (1998) Cancer Res. , vol.58 , pp. 1068-1073
    • Silber, J.R.1    Bobola, M.S.2    Ghatan, S.3    Blank, A.4    Kolstoe, D.D.5    Berger, M.S.6
  • 203
    • 0031869758 scopus 로고    scopus 로고
    • Predicting response to cancer chemotherapy: The role of p53
    • 203 Weller M. (1998) Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 292: 435-445
    • (1998) Cell Tissue Res. , vol.292 , pp. 435-445
    • Weller, M.1
  • 204
    • 0031705691 scopus 로고    scopus 로고
    • p53 and brain tumors: From gene mutations to gene therapy
    • 204 Fulci G., Ishii N. and Van Meir E. G. (1998) p53 and brain tumors: from gene mutations to gene therapy. Brain Pathol. 8: 599-613
    • (1998) Brain Pathol. , vol.8 , pp. 599-613
    • Fulci, G.1    Ishii, N.2    Van Meir, E.G.3
  • 206
    • 0031813862 scopus 로고    scopus 로고
    • Suppression of human glioma growth by adenovirus-mediated Rb gene transfer
    • 206 Fueyo J., Gomez Manzano C., Yung W. K., Liu T. J., Alemany R., Bruner J. M. et al. (1998) Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology 50: 1307-1315
    • (1998) Neurology , vol.50 , pp. 1307-1315
    • Fueyo, J.1    Gomez Manzano, C.2    Yung, W.K.3    Liu, T.J.4    Alemany, R.5    Bruner, J.M.6
  • 207
    • 0030070484 scopus 로고    scopus 로고
    • CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated
    • 207 Ueki K., Ono Y., Henson J. W., Efird J. T., Deimling A. von and Louis D. N. (1996) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 56: 150-153
    • (1996) Cancer Res. , vol.56 , pp. 150-153
    • Ueki, K.1    Ono, Y.2    Henson, J.W.3    Efird, J.T.4    Von Deimling, A.5    Louis, D.N.6
  • 208
    • 3643119742 scopus 로고    scopus 로고
    • The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells
    • 208 Furnari F. B., Huang H. J. and Cavenee W. K. (1998) The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res. 58: 5002-5008
    • (1998) Cancer Res. , vol.58 , pp. 5002-5008
    • Furnari, F.B.1    Huang, H.J.2    Cavenee, W.K.3
  • 209
    • 0033556443 scopus 로고    scopus 로고
    • Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: Differential involvement of focal adhesion kinase and p130Cas
    • 209 Tamura M., Gu J., Takino T. and Yamada K. M. (1999) Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res. 59: 442-449
    • (1999) Cancer Res. , vol.59 , pp. 442-449
    • Tamura, M.1    Gu, J.2    Takino, T.3    Yamada, K.M.4
  • 210
    • 0032431028 scopus 로고    scopus 로고
    • PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells
    • 210 Li D. M. and Sun H. (1998) PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc. Natl. Acad. Sci. USA 95: 15406-15411
    • (1998) Proc. Natl. Acad. Sci. USA , vol.95 , pp. 15406-15411
    • Li, D.M.1    Sun, H.2
  • 211
    • 0032566064 scopus 로고    scopus 로고
    • Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas
    • 211 Maier D., Zhang Z., Taylor E, Hamou M. F., Gratzl O., Van Meir E. G. et al. (1998) Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas. Oncogene 16: 3331-3335
    • (1998) Oncogene , vol.16 , pp. 3331-3335
    • Maier, D.1    Zhang, Z.2    Taylor, E.3    Hamou, M.F.4    Gratzl, O.5    Van Meir, E.G.6
  • 212
    • 0033536225 scopus 로고    scopus 로고
    • PTEN gene transfer in human malignant glioma: Sensitization to irradiation and CD95L-induced apoptosis
    • 212 Wick W., Furnari F. B., Naumann U., Cavenee W. K. and Weller M. (1999) PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene 18: 3936-3943
    • (1999) Oncogene , vol.18 , pp. 3936-3943
    • Wick, W.1    Furnari, F.B.2    Naumann, U.3    Cavenee, W.K.4    Weller, M.5
  • 213
    • 0030979773 scopus 로고    scopus 로고
    • Double identity for proteins of the Bcl-2 family
    • 213 Reed J. C. (1997) Double identity for proteins of the Bcl-2 family. Nature 387: 773-776
    • (1997) Nature , vol.387 , pp. 773-776
    • Reed, J.C.1
  • 214
    • 0029010631 scopus 로고
    • Prolooncogene bcl-2 gene transfer abrogates Fas/ APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation
    • 214 Weller M., Malipiero U., Aguzzi A., Reed J. C. and Fontana A. (1995) Prolooncogene bcl-2 gene transfer abrogates Fas/ APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest. 95: 2633-2643
    • (1995) J. Clin. Invest. , vol.95 , pp. 2633-2643
    • Weller, M.1    Malipiero, U.2    Aguzzi, A.3    Reed, J.C.4    Fontana, A.5
  • 215
    • 0030892234 scopus 로고    scopus 로고
    • Apoptosis by death factor
    • 215 Nagata S. (1997) Apoptosis by death factor. Cell 88: 355-365
    • (1997) Cell , vol.88 , pp. 355-365
    • Nagata, S.1
  • 217
    • 0027161158 scopus 로고
    • Effect of bcl-2 on Fas antigen-mediated cell death
    • 217 Itoh N., Tsujimoto Y. and Nagata S. (1993) Effect of bcl-2 on Fas antigen-mediated cell death. J. Immunol. 151: 621-627
    • (1993) J. Immunol. , vol.151 , pp. 621-627
    • Itoh, N.1    Tsujimoto, Y.2    Nagata, S.3
  • 218
    • 17444424930 scopus 로고    scopus 로고
    • Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
    • 218 Pitti R. M., Marsters S. A., Lawrence D. A., Roy M., Kischkel F. C., Dowd P. et al. (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396: 699-703
    • (1998) Nature , vol.396 , pp. 699-703
    • Pitti, R.M.1    Marsters, S.A.2    Lawrence, D.A.3    Roy, M.4    Kischkel, F.C.5    Dowd, P.6
  • 219
    • 0029840585 scopus 로고    scopus 로고
    • Fas ligand and immune evasion
    • 219 Nagata S. (1996) Fas ligand and immune evasion. Nat. Med. 2: 1306-1307
    • (1996) Nat. Med. , vol.2 , pp. 1306-1307
    • Nagata, S.1
  • 220
    • 0030895084 scopus 로고    scopus 로고
    • Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?
    • 220 Saas P., Walker P. R., Hahne M., Quiquerez A. L., Schnuriger V., Perrin G. et al. (1997) Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 99: 1173-1178
    • (1997) J. Clin. Invest. , vol.99 , pp. 1173-1178
    • Saas, P.1    Walker, P.R.2    Hahne, M.3    Quiquerez, A.L.4    Schnuriger, V.5    Perrin, G.6
  • 221
    • 0030883910 scopus 로고    scopus 로고
    • CD9S-dependent T cell killing by glioma cells expressing CD95L: More on tumor immune escape, the CD95 counterattack, and the immune privilege of the brain
    • 221 Weller M., Weinstock C., Will C., Wagenknecht B., Dichgans J., Lang F. et al. (1997) CD9S-dependent T cell killing by glioma cells expressing CD95L: more on tumor immune escape, the CD95 counterattack, and the immune privilege of the brain. Cell Physiol. Biochem. 7: 282-288
    • (1997) Cell Physiol. Biochem. , vol.7 , pp. 282-288
    • Weller, M.1    Weinstock, C.2    Will, C.3    Wagenknecht, B.4    Dichgans, J.5    Lang, F.6
  • 222
    • 0030610033 scopus 로고    scopus 로고
    • Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors
    • 222 Gratas C., Tohma Y., Van Meir E. G., Klein M., Tenan M., Ishii N. et al. (1997) Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 7: 863-869
    • (1997) Brain Pathol. , vol.7 , pp. 863-869
    • Gratas, C.1    Tohma, Y.2    Van Meir, E.G.3    Klein, M.4    Tenan, M.5    Ishii, N.6
  • 223
    • 0032575714 scopus 로고    scopus 로고
    • Death receptors: Signaling and modulation
    • 223 Ashkenazi A. and Dixit V. M. (1998) Death receptors: signaling and modulation. Science 281: 1305-1308
    • (1998) Science , vol.281 , pp. 1305-1308
    • Ashkenazi, A.1    Dixit, V.M.2
  • 224
    • 0031472042 scopus 로고    scopus 로고
    • Cell death: TRAIL and its receptors
    • 224 Golstein P. (1997) Cell death: TRAIL and its receptors. CUTT. Biol. 7: R750-753
    • (1997) CUTT. Biol. , vol.7
    • Golstein, P.1
  • 225
    • 0027420929 scopus 로고
    • Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells
    • 225 Leithäuser F., Dhein J., Mechtersheimer G., Koretz K., Bruderlein S., Henne C. et al. (1993) Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest. 69: 415-429
    • (1993) Lab. Invest. , vol.69 , pp. 415-429
    • Leithäuser, F.1    Dhein, J.2    Mechtersheimer, G.3    Koretz, K.4    Bruderlein, S.5    Henne, C.6
  • 226
    • 0029985912 scopus 로고    scopus 로고
    • Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover
    • 226 French L. E., Hahne M., Viard I., Radlgruber G., Zanone R., Becker K. et al. (1996) Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell Biol. 133: 335-343
    • (1996) J. Cell Biol. , vol.133 , pp. 335-343
    • French, L.E.1    Hahne, M.2    Viard, I.3    Radlgruber, G.4    Zanone, R.5    Becker, K.6
  • 227
    • 0028051493 scopus 로고
    • Fas ligation triggers apoptosis in macrophages but not endothelial cells
    • 227 Richardson B. C., Lalwani N. D., Johnson K. J. and Marks R. M. (1994) Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur. J. Immunol. 24: 2640-2645
    • (1994) Eur. J. Immunol. , vol.24 , pp. 2640-2645
    • Richardson, B.C.1    Lalwani, N.D.2    Johnson, K.J.3    Marks, R.M.4
  • 228
    • 0033557734 scopus 로고    scopus 로고
    • CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses: A key role in brain inflammation?
    • 228 Saas P., Boucraut J., Quiquerez A. L., Schnuriger V., Perrin G., Desplat-Jego S. et al. (1999) CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses: a key role in brain inflammation? J. Immunol. 162: 2326-2333
    • (1999) J. Immunol. , vol.162 , pp. 2326-2333
    • Saas, P.1    Boucraut, J.2    Quiquerez, A.L.3    Schnuriger, V.4    Perrin, G.5    Desplat-Jego, S.6
  • 229
    • 0344258462 scopus 로고    scopus 로고
    • Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-alpha, or IFN-gamma
    • 229 Choi C., Park J. Y., Lee J., Lim J. H., Shin E. C., Ahn Y. S. et al. (1999) Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-alpha, or IFN-gamma. J. Immunol. 162: 1889-1895
    • (1999) J. Immunol. , vol.162 , pp. 1889-1895
    • Choi, C.1    Park, J.Y.2    Lee, J.3    Lim, J.H.4    Shin, E.C.5    Ahn, Y.S.6
  • 230
    • 0028866388 scopus 로고
    • Fas antigen expression in brains of patients with Alzheimer-type dementia
    • 230 Nishimura T., Akiyama H., Yonehara S., Kondo H., Ikeda K., Kato M. et al. (1995) Fas antigen expression in brains of patients with Alzheimer-type dementia. Brain Res. 695: 137-145
    • (1995) Brain Res. , vol.695 , pp. 137-145
    • Nishimura, T.1    Akiyama, H.2    Yonehara, S.3    Kondo, H.4    Ikeda, K.5    Kato, M.6
  • 231
    • 0029960673 scopus 로고    scopus 로고
    • Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain
    • 231 Dowling P., Shang G., Raval S., Menonna J., Cook S. and Husar W. (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J. Exp. Med. 184: 1513-1518
    • (1996) J. Exp. Med. , vol.184 , pp. 1513-1518
    • Dowling, P.1    Shang, G.2    Raval, S.3    Menonna, J.4    Cook, S.5    Husar, W.6
  • 235
    • 13344285339 scopus 로고
    • Identification and characterization of a new member of the TNF family that induces apoptosis
    • 235 Wiley S. R., Schooley K., Smolak P. J., Din W. S., Huang C. P., Nicholl J. K. et al. (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682
    • (1995) Immunity , vol.3 , pp. 673-682
    • Wiley, S.R.1    Schooley, K.2    Smolak, P.J.3    Din, W.S.4    Huang, C.P.5    Nicholl, J.K.6
  • 237
    • 0030792712 scopus 로고    scopus 로고
    • Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
    • 237 Sheridan J. P., Marsters S. A., Pitti R. M., Gurney A., Skubatch M., Baldwin D. et al. (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821
    • (1997) Science , vol.277 , pp. 818-821
    • Sheridan, J.P.1    Marsters, S.A.2    Pitti, R.M.3    Gurney, A.4    Skubatch, M.5    Baldwin, D.6
  • 238
    • 0030762815 scopus 로고    scopus 로고
    • An antagonist decoy receptor and a death domain-containing receptor for TRAIL
    • 238 Pan G., Ni J., Wei Y. F., Yu G., Gentz R. and Dixit V. M. (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815-818
    • (1997) Science , vol.277 , pp. 815-818
    • Pan, G.1    Ni, J.2    Wei, Y.F.3    Yu, G.4    Gentz, R.5    Dixit, V.M.6
  • 241
    • 0032509754 scopus 로고    scopus 로고
    • Synergy of CD95 ligand and teniposide: No role of eleavable complex formation and enhanced CD95 expression
    • 241 Winter S., Roth W., Dichgans J. and Weller M. (1998) Synergy of CD95 ligand and teniposide: no role of eleavable complex formation and enhanced CD95 expression. Eur. J. Pharmacol. 341: 323-328
    • (1998) Eur. J. Pharmacol. , vol.341 , pp. 323-328
    • Winter, S.1    Roth, W.2    Dichgans, J.3    Weller, M.4
  • 242
    • 0032159285 scopus 로고    scopus 로고
    • Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNa synthesis but not changes in CD95 or CD95L protein expression
    • 242 Winter S. and Weller M. (1998) Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression. J. Pharmacol. Exp. Ther. 286: 1374-1382
    • (1998) J. Pharmacol. Exp. Ther. , vol.286 , pp. 1374-1382
    • Winter, S.1    Weller, M.2
  • 243
    • 0031588345 scopus 로고    scopus 로고
    • Topoisomerase-I inhibitors for human malignant glioma: Differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone
    • 243 Weller M., Winter S., Schmidt C., Esser P., Fontana A., Dichgans J. et al. (1997) Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone. Int. J. Cancer 73: 707-714
    • (1997) Int. J. Cancer , vol.73 , pp. 707-714
    • Weller, M.1    Winter, S.2    Schmidt, C.3    Esser, P.4    Fontana, A.5    Dichgans, J.6
  • 244
    • 0031852453 scopus 로고    scopus 로고
    • Chemotherapy primes malignant glioma cells for CD95 ligand-induced apoptosis up-stream of caspase 3 activation
    • 244 Hueber A., Winter S. and Weller M. (1998) Chemotherapy primes malignant glioma cells for CD95 ligand-induced apoptosis up-stream of caspase 3 activation. Eur. J. Pharmacol. 352: 111-115
    • (1998) Eur. J. Pharmacol. , vol.352 , pp. 111-115
    • Hueber, A.1    Winter, S.2    Weller, M.3
  • 245
    • 0040419494 scopus 로고    scopus 로고
    • Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53
    • 245 Müller M., Strand S., Hug H., Heinemann E. M., Walczak H., Hofmann W. J. et al. (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99: 403-413
    • (1997) J. Clin. Invest. , vol.99 , pp. 403-413
    • Müller, M.1    Strand, S.2    Hug, H.3    Heinemann, E.M.4    Walczak, H.5    Hofmann, W.J.6
  • 246
    • 0029935682 scopus 로고    scopus 로고
    • Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
    • 246 Friesen C., Herr I., Krammer P. H. and Debatin K. M. (1996) Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2: 574-577
    • (1996) Nat. Med. , vol.2 , pp. 574-577
    • Friesen, C.1    Herr, I.2    Krammer, P.H.3    Debatin, K.M.4
  • 247
    • 0030752603 scopus 로고    scopus 로고
    • The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells
    • 247 Fulda S., Sieverts H., Friesen C., Herr I. and Debatin K. M. (1997) The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 57: 3823-3829
    • (1997) Cancer Res. , vol.57 , pp. 3823-3829
    • Fulda, S.1    Sieverts, H.2    Friesen, C.3    Herr, I.4    Debatin, K.M.5
  • 248
    • 0030806351 scopus 로고    scopus 로고
    • Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions
    • 248 Eischen C. M., Kottke T. J., Martins L. M., Basi G. S., Tung J. S., Earnshaw W. C. et al. (1997) Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 90: 935-943
    • (1997) Blood , vol.90 , pp. 935-943
    • Eischen, C.M.1    Kottke, T.J.2    Martins, L.M.3    Basi, G.S.4    Tung, J.S.5    Earnshaw, W.C.6
  • 249
    • 0030781018 scopus 로고    scopus 로고
    • Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way
    • 249 Gamen S., Anel A., Lasierra P., Alava M. A., Martinez Lorenzo M. J., Pineiro A. et al. (1997) Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FFBS Lett. 417: 360-364
    • (1997) FFBS Lett. , vol.417 , pp. 360-364
    • Gamen, S.1    Anel, A.2    Lasierra, P.3    Alava, M.A.4    Martinez Lorenzo, M.J.5    Pineiro, A.6
  • 250
    • 0030744833 scopus 로고    scopus 로고
    • Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells
    • 250 Villunger A., Egle A., Kos M., Hartmann B. L., Geley S., Kofler R. et al. (1997) Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res. 57: 3331-3334
    • (1997) Cancer Res. , vol.57 , pp. 3331-3334
    • Villunger, A.1    Egle, A.2    Kos, M.3    Hartmann, B.L.4    Geley, S.5    Kofler, R.6
  • 253
    • 0031472398 scopus 로고    scopus 로고
    • Gene transfer of Fas ligand induces tumor regression in vivo
    • 253 Arai H., Gordon D., Nabel E. G. and Nabel G. J. (1997) Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. USA 94: 13862-13867
    • (1997) Proc. Natl. Acad. Sci. USA , vol.94 , pp. 13862-13867
    • Arai, H.1    Gordon, D.2    Nabel, E.G.3    Nabel, G.J.4
  • 254
    • 0031042972 scopus 로고    scopus 로고
    • Antitumor effect of locally produced CD95 ligand
    • 254 Seino K., Kayagaki N., Okumura K. and Yagita H. (1997) Antitumor effect of locally produced CD95 ligand. Nat. Med. 3: 165-170
    • (1997) Nat. Med. , vol.3 , pp. 165-170
    • Seino, K.1    Kayagaki, N.2    Okumura, K.3    Yagita, H.4
  • 255
    • 0032008535 scopus 로고    scopus 로고
    • Retroviral transfer of CPP32beta gene into malignant gliomas in vitro and in vivo
    • 255 Kondo S., Tanaka Y., Kondo Y., Ishizaka Y., Hitomi M., Haqqi T. et al. (1998) Retroviral transfer of CPP32beta gene into malignant gliomas in vitro and in vivo. Cancer Res. 58: 962-967
    • (1998) Cancer Res. , vol.58 , pp. 962-967
    • Kondo, S.1    Tanaka, Y.2    Kondo, Y.3    Ishizaka, Y.4    Hitomi, M.5    Haqqi, T.6
  • 257
    • 0030467622 scopus 로고    scopus 로고
    • Retroviral delivery and tetracycline-dependent expression of IL-1 beta-converting enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumor cells
    • 257 Yu J. S., Sena-Esteves M., Paulus W., Breakefield X. O. and Reeves S. A. (1996) Retroviral delivery and tetracycline-dependent expression of IL-1 beta-converting enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumor cells. Cancer Res. 56: 5423-5427
    • (1996) Cancer Res. , vol.56 , pp. 5423-5427
    • Yu, J.S.1    Sena-Esteves, M.2    Paulus, W.3    Breakefield, X.O.4    Reeves, S.A.5
  • 258
    • 0032079348 scopus 로고    scopus 로고
    • APO2 ligand: A novel lethal weapon against malignant glioma?
    • 258 Rieger J., Naumann U., Glaser T., Ashkenazi A. and Weller M. (1998) APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett. 427: 124-128
    • (1998) FEBS Lett. , vol.427 , pp. 124-128
    • Rieger, J.1    Naumann, U.2    Glaser, T.3    Ashkenazi, A.4    Weller, M.5
  • 259
    • 9844225051 scopus 로고    scopus 로고
    • Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies
    • 259 Snell V., Clodi K., Zhao S., Goodwin R., Thomas E. K., Morris S. W. et al. (1997) Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br. J. Haematol. 99: 618-624
    • (1997) Br. J. Haematol. , vol.99 , pp. 618-624
    • Snell, V.1    Clodi, K.2    Zhao, S.3    Goodwin, R.4    Thomas, E.K.5    Morris, S.W.6
  • 260
    • 0032169208 scopus 로고    scopus 로고
    • TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells
    • 260 Thomas W. D. and Hersey P. (1998) TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J. Immunol. 161: 2195-2200
    • (1998) J. Immunol. , vol.161 , pp. 2195-2200
    • Thomas, W.D.1    Hersey, P.2
  • 261
    • 0032530612 scopus 로고    scopus 로고
    • Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
    • 261 Griffith T. S., Chin W. A., Jackson G. C., Lynch D. H. and Kubin M. Z. (1998) Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161: 2833-2840
    • (1998) J. Immunol. , vol.161 , pp. 2833-2840
    • Griffith, T.S.1    Chin, W.A.2    Jackson, G.C.3    Lynch, D.H.4    Kubin, M.Z.5
  • 262
    • 0030943324 scopus 로고    scopus 로고
    • Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells
    • 262 Mariani S. M., Matiba B., Armandola E. A. and Krammer P. H. (1997) Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J. Cell Biol. 137: 221-229
    • (1997) J. Cell Biol. , vol.137 , pp. 221-229
    • Mariani, S.M.1    Matiba, B.2    Armandola, E.A.3    Krammer, P.H.4
  • 263
    • 17544367410 scopus 로고    scopus 로고
    • Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
    • 263 Pitti R. M., Marsters S. A., Ruppert S., Donahue C. J., Moore A. and Ashkenazi A. (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271: 12687-12690
    • (1996) J. Biol. Chem. , vol.271 , pp. 12687-12690
    • Pitti, R.M.1    Marsters, S.A.2    Ruppert, S.3    Donahue, C.J.4    Moore, A.5    Ashkenazi, A.6
  • 264
    • 0032929520 scopus 로고    scopus 로고
    • Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
    • 264 Walczak H., Miller R. E., Ariail K., Gliniak B., Griffith T. S., Kubin M. et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5: 157-163
    • (1999) Nat. Med. , vol.5 , pp. 157-163
    • Walczak, H.1    Miller, R.E.2    Ariail, K.3    Gliniak, B.4    Griffith, T.S.5    Kubin, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.